Converted by EDGARwiz

0001551163-14-000244.txt : 20140819 0001551163-14-000244.hdr.sgml : 20140819 20140819123113 ACCESSION NUMBER: 0001551163-14-000244 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140630 FILED AS OF DATE: 20140819 DATE AS OF CHANGE: 20140819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROTECT PHARMACEUTICAL Corp CENTRAL INDEX KEY: 0001493526 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271877179 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54001 FILM NUMBER: 141051306 BUSINESS ADDRESS: STREET 1: 2681 EAST PARLEYS WAY STREET 2: SUITE 204 CITY: SALT LAKE CITY STATE: UT ZIP: 84109 BUSINESS PHONE: 8013223401 MAIL ADDRESS: STREET 1: 2681 EAST PARLEYS WAY STREET 2: SUITE 204 CITY: SALT LAKE CITY STATE: UT ZIP: 84109 10-Q 1 f10qjune302014vedgar2.htm Converted by EDGARwiz

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

For the Quarter Ended June 30, 2014

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

For the transition period from _____ to ______

Commission File Number 000-54001

PROTECT PHARMACEUTICAL CORPORATION

(Exact name of registrant as specified in its charter)

Nevada

27-1877179

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer Identification No.)

2681 Parleys Way, Suite 204, Salt Lake City, UT 84109

(Address of principal executive offices)

(801) 322-3401

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ¨ No x

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company


Large accelerated filer ¨		Accelerated filer ¨
Non-accelerated filer ¨		Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date.


Class	Outstanding as of August 19, 2014

Common Stock, $0.005 par value	44,573,012

TABLE OF CONTENTS


Heading		Page

	PART I— FINANCIAL INFORMATION

Item 1.	Unaudited Financial Statements	3

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	15

Item 4.	Controls and Procedures	15


	PART II— OTHER INFORMATION

Item 1.	Legal Proceedings	16

Item 1A.	Risk Factors	16

Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	16

Item 3.	Defaults Upon Senior Securities	16

Item 4.	Mine Safety Disclosures	16

Item 5.	Other Information	16

Item 6.	Exhibits	16

	Signatures	17

PART I — FINANCIAL INFORMATION


Item 1.	Financial Statements

The accompanying unaudited balance sheets of Protect Pharmaceutical Corporation at June 30, 2014 and related unaudited statements of operations, and cash flows for the three and six months ended June 30, 2014, have been prepared by management in conformity with United States generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. We suggest that these financial statements be read in conjunction with the financial statements and notes thereto included in the December 31, 2013 audited financial statements included in our Form 10-K. Operating results for the period ended June 30, 2014, are not necessarily indicative of the results that can be expected for the fiscal year ending December 31, 2014 or any other subsequent period.


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
Condensed Balance Sheets

			June 30, 2014		December 31, 2013
ASSETS
CURRENT ASSETS

	Cash			591			681

		Total Current Assets		591			681

		TOTAL ASSETS		591			681


LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES

	Accounts payable and accrued expenses			61,954		60,104
	Accounts payable - related parties			21,714		23,939
	Notes payable - related parties			34,439		24,940
	Other accrued expenses			486,826		486,826

		Total Current Liabilities		604,933		595,809

		TOTAL LIABILITIES		604,933		595,809

STOCKHOLDERS' DEFICIT

	Preferred stock; 10,000,000 shares authorized,at $0.001 par value, no shares issued or outstanding			-		-

	Common stock; 100,000,000 shares authorized,at $0.005 par value, 44,573,012 and 44,573,012 shares issued and outstanding, respectively			222,865		222,865
	Additional paid-in capital			8,357,980		8,354,980
	Deficit accumulated during the development stage			(9,185,187)		(9,172,973)

		Total Stockholders' Deficit		(604,342)		(595,128)

		TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		591		681

The accompanying notes are an integral part of these condensed financial statements.


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
Condensed Statements of Operations

			For the Three Months Ended June 30, 2014		For the Three Months Ended June 30, 2013		For the Six Months Ended June 30, 2014		For the Six Months Ended June 30, 2013		From Inception on August 5, 1987 Through June 30, 2014
REVENUES
REVENUES				-		-		-		-		-

EXPENSES

	Research and development			-		-		-		-		1,353,540
	Professional Fees			8,630		9,727		9,125		11,313		1,507,868
	Executive compensation			1,500		1,500		3,000		3,000		5,897,730
	General and administrative			45		46		89		90		447,209
		Total Expenses		10,175		11,273		12,214		14,403		9,206,347

LOSS FROM OPERATIONS				(10,175)		(11,273)		(12,214)		(14,403)		(9,206,347)

OTHER INCOME

	Gain on sale of patents			-		-		-		-		640,000
		Total Other Income		-		-		-		-		640,000

				(10,175)		(11,273)		(12,214)		(14,403)		(8,566,347)

LOSS FROM DISCONTINUED OPERATIONS				-		-		-		-		(4,340,551)

	Income Taxes			-		-		-		-		-
PROFIT LOSS				(10,175)		(11,273)		(12,214)		(14,403)		(12,906,898)

BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK				(0.00)		(0.00)		(0.00)		(0.00)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING				44,573,012		44,573,012		44,573,012		44,573,012

The accompanying notes are an integral part of these condensed financial statements.


PROTECT PHARMACEUTICAL CORPORATION
(A Development Stage Company)
CondensedStatements of Cash Flows

			For the Six Months Ended June 30, 2014		For the Six Months Ended June 30, 2013		From Inception on August 5, 1987 Through June 30, 2014

OPERATING ACTIVITIES
	Net loss			(12,214)		(14,403)		(12,906,898)

Adjustments to reconcile loss to net cash flows from operating activities
	Common stock issued for services			-		-		9,904,653
	Services contributed by officers			3,000		3,000		15,000
	Common stock issued for research and development costs			-		-		1,250,000
	Loss from disposition of subsidiary			-		-		564,300
	Expenses paid on behalf of the Company			9,499		4,860		99,958
	Gain on sale of patents			-		-		(640,000)
Changes in operating assets and liabilities
	Accounts payable			1,850		(1,521)		61,955
	Accounts payable - related parties			(2,225)		7,975		165,476
	Prepaid expenses			-		-		491,667
	Other accrued expenses			-		-		486,826

		Net Cash Provided by Operating Activities		(90)		(89)		(507,062)

INVESTING ACTIVITIES
	Proceeds from sale of patent			-		-		640,000

		Net Cash Used in Financing Activities		-		-		640,000

FINANCING ACTIVITIES				-		-		-
	Capital contributed by officer			-		-		13,046
	Proceeds from related party payable			-		-		100
	Repayment of related party payable			-		-		(145,493)

		Net Cash Provided by (Used in) Financing Activities		-		-		(132,347)

NET INCREASE (DECREASE) IN CASH				(90)		(89)		591

CASH AT BEGINNING OF PERIOD				681		860		-

CASH AT END OF PERIOD				591		771		591

SUPPLEMENTAL CASH FLOW INFORMATION:
	NON-CASH FINANCING ACTIVITIES:
		Common stock issued for prepaid services		-		-		750,000

The accompanying notes are an integral part of these condensed financial statements.

PROTECT PHARMACEUTICAL CORPORATION

(A Development Stage Company)

Condensed Notes to Unaudited Financial Statements

June 30, 2014 and December 31, 2013

NOTE 1 - CONDENSED FINANCIAL STATEMENTS

The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2014, and for all periods presented herein, have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2013 audited financial statements. The results of operations for the periods ended June 30, 2014and 2013 are not necessarily indicative of the operating results for the full years.

NOTE 2 - GOING CONCERN

The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have significant cash or other material assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. It is the intent of the Company to seek a merger with an existing, operating company. In the interim, shareholders of the Company have committed to meeting its minimal operating expenses

NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basic (Loss) per Common Share

Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of June 30, 2014 and 2013.

Recent Accounting Pronouncements

The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.

PROTECT PHARMACEUTICAL CORPORATION

(A Development Stage Company)

Condensed Notes to Unaudited Financial Statements

June 30, 2014 and December 31, 2013

NOTE 4 – RELATED-PARTY TRANSACTIONS

The Company owed trade accounts payable to a related party in the amount of $21,714, and $23,939, as of June 30, 2014, and December 31, 2013, respectively. These amounts related to accounting and consulting services provided by an entity that is partially owned by a Company officer.

The Company has recorded advances from related parties and expenses paid by related parties on behalf of the Company as related party payables. As of June 30, 2014 and December 31, 2013, respectively, the related party payable outstanding balance totaled $34,439 and $24,940 . These payables are non-interest bearing, unsecured, and are due on demand.

Contributed Capital

During the six months ended June 30, 2014 and 2013, a related-party has contributed various administrative services to the Company. These services have been valued at $3,000 for the six month periods then ended.

NOTE 5 – SALE OF PATENTS

On January 31, 2011, Protect Pharmaceutical Corporation (the “Company”) finalized and closed a Patent Purchase Agreement (the “Agreement”) with Grünenthal GmbH (“Grünenthal”), a company organized under the laws of Germany. Pursuant to the terms of the Agreement, the Company sold to Grünenthal all of the Company’s rights title and interest in and to certain inventions described and claimed in certain patents and patent applications (collectively “the Patents”), including without limitation, all extensions, continuations, provisions, derivatives and related applications thereof. The Patents relate to Opioid Formulations and Methods of treating acute and chronic pain.

In exchange for the Patents, Grünenthal paid the Company $1,600,000. The Company originally acquired the subject Patents sold to Grünenthal, together with other inventions and patents, in February 2010 pursuant to a Patent Acquisition Agreement with Nectid, Inc. (“Nectid”), a privately held New Jersey company. Under the terms of the Patent Acquisition Agreement and Addendum, the Company agreed that in the event the Company sold out right any of the patents acquired from Nectid without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Company. Accordingly, the Company realized 40%, or $640,000 from the proceeds of the sale and the balance will be paid to Nectid. The Company retains all other inventions, patents and technologies initially acquired from Nectid.

NOTE 6 - STOCK PURCHASE AGREEMENT

On June 17, 2011, Protect Pharmaceutical Corporation finalized the execution of an Investment Agreement with Kodiak Capital Group, LLC, a Delaware limited liability company. The Agreement provides the Company with an equity line whereby the Company can sell to Kodiak, from time-to-time, shares of the Company’s common stock up to an aggregate value of $10 million dollars over a two-year period. As part of the agreement, the Company will file with the SEC a registration statement under the Securities Act of 1933 to register the common stock that may be sold to Kodiak pursuant to the Agreement.

PROTECT PHARMACEUTICAL CORPORATION

(A Development Stage Company)

Condensed Notes to Unaudited Financial Statements

June 30, 2014 and December 31, 2013

NOTE 6 - STOCK PURCHASE AGREEMENT (Continued)

Under the terms of the Agreement, The Company has the right to deliver to Kodiak a “put notice” stating the dollar amount of common shares we intend to sell to Kodiak, up to $250,000. The amount that the Company is entitled to sell to Kodiak under any single put notice will be equal to, at Kodiak's election, either: (i) 200% of the average daily volume (U.S. market only) of the common stock for the three trading days prior to the put notice, multiplied by the average of the three daily closing bid prices immediately preceding the put notice date; or (ii) up to $250,000.

The Company cannot submit a new put notice until after the closing of the previous notice. The purchase price for the shares pursuant to the put notice will be equal to 92% of the lowest closing best bid price of the common stock during the five trading days after the put notice is delivered. The shares must be paid for and share certificates delivered within the “pricing period,” which is seven days from the date the put notice is delivered.

The Company has the option to specify a floor price for any put notice. In the event our shares fall below the floor price, the put will be temporarily suspended. The put will resume if, during the pricing period for that put, the common stock trades above the floor price.

The Company has agreed to pay to Kodiak an initial fee of 150,000 shares of common stock following execution of the Agreement. Also, the Company has agreed to pay Kodiak a commitment fee equal to 3% of the total amount of the commitment, payable as follows: (i) 25% on the first closing of a put notice; (ii) 25% on the second closing, (iii) 25% on the third closing; and (iv) 25% on the fourth closing or eight months from execution of the Agreement. The commitment fee is payable in Company common stock.

In connection with the Agreement, we entered into a Registration Rights Agreement with Kodiak, whereby the Company agreed to register with the SEC the shares to be issued pursuant to the Agreement. The Company must prepare and file within 90 days from the date of the Agreement, a registration statement under the Securities Act of 1933.

The Company intended to use the proceeds from the sale of common stock pursuant to the Agreement for general corporate and working capital purposes and acquisitions of assets, businesses or operations, or for other purposes that the board of directors deems to be in the best interest of the Company.

As of December 31, 2013 the Company has not initiated any activity with respect to the Investment Agreement other than the initial issuance of 150,000 common shares. The Company has not registered with the SEC the shares to be issued to Kodak. The Agreement expired on June 17, 2014.

NOTE 6 – SUBSEQUENT EVENTS

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report.


Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations

The following information should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere in this Form 10-Q.

Forward-Looking and Cautionary Statements

This report contains forward-looking statements relating to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “will” “should," “expect," "intend," "plan," anticipate," "believe," "estimate," "predict," "potential," "continue," or similar terms, variations of such terms or the negative of such terms. These statements are only predictions and involve known and unknown risks, uncertainties and other factors included in our periodic reports with the SEC. Although forward-looking statements, and any assumptions upon which they are based, are made in good faith and reflect our current judgment, actual results could differ materially from those anticipated in such statements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

We are considered a development stage company with limited capital and no current revenues. We do not expect to realize revenues until we are successful in developing, achieving approval and marketing one or more of our drug delivery technologies or solutions. We anticipate that in the near term, ongoing expenses, including the costs associated with the preparation and filing of requisite reports with the SEC, will be paid for by advances from stockholders or from the private sale of securities, either debt or equity. However, there is no assurance that we will be able to realize such funds on terms favorable to us, or at all.

Results of Operations

Three Months Ended June 30, 2014 and 2013

We did not realize revenues for the three-month periods ended June 30, 2014 and 2013 nor from inception. During the three months ended June 30, 2014, we recorded total expenses of $10,175, consisting of $8,630 in professional fees, $1,500 in executive compensation and $45 in general and administrative expenses. In the comparable period of 2013 we recorded expenses totaling $11,273, consisting of $9,727 in professional fees, $1,500 in executive compensation and $46 in general and administrative expenses. These factors resulted in a net loss for the three months ended June 30, 2014 in the amount of $10,175 ($0.00 per share), compared to net loss of $11,273 ($0.00 per share) for the three months ended June 30, 2013.

Six Months Ended June 30, 2014 and 2013

We did not realize revenues for the six-month periods ended June 30, 2014 and 2013. During the six months ended June 30, 2014, we recorded total expenses of $12,214, consisting of $9,125 in professional fees, $3,000 in executive compensation and $89 in general and administrative expenses. In the comparable period of 2013 we recorded expenses totaling $14,403, consisting of $11,313 in professional fees, $3,000 in executive compensation and $90 in general and administrative expenses. These factors resulted in a net loss for the six months ended June 30, 2014 in the amount of $12,214 ($0.00 per share), compared to net loss of $14,403 ($0.00 per share) for the six months ended June 30, 2014.

Liquidity and Capital Resources

Total assets at June 30, 2014 were $591 in cash, compared to $681 in cash at December 31, 2013. Total liabilities at June 30, 2014 were $604,933, consisting of $486,826 in other accrued expenses, accounts payable and accrued expenses of $61,954, Notes payable – related parties of $34,439 and accounts payable - related parties of $21,714. At December 31, 2013, total liabilities were $595,809, consisting of $486,826 in other accrued expenses, accounts payable and accrued expenses of $60,104, Notes payable – related parties of $24,940 and accounts payable - related parties of $23,939.

Because we currently have no revenues, for the immediate future we believe we will have to rely on our existing cash reserves and potential loans from stockholders to continue to implement our business activities. There is no assurance that our stockholders will continue indefinitely to provide additional funds or pay our expenses. It is likely the only other source of funding future operations will be through the private sale of our securities, either equity or debt.

At June 30, 2014, we had stockholders’ deficit of $604,342 compared to stockholders’ deficit of $595,128 at December 31, 2013. The increased deficit is primarily due to the net loss of $12,214 during the six months ended June 30, 2014.

Plan of Operation

We intend to research and develop new generation drug delivery technologies that we believe will enable products with improved clinical benefits. We believe our drugs could offer enhanced pain relief and reduced tolerance/physical dependence, reduced addiction potential and side effects compared to existing neuropathic and fibromyalgia drugs and opioid painkillers. We intend to conduct our research and development through collaborative programs. We anticipate relying on arrangements with third party drug developers such as contract research organizations and clinical research sites for a significant portion of our product development efforts.

We expect to incur significant operating losses for the next several years and until we are able to formulate a commercially viable product. We also expect to continue to incur significant operating and capital expenditures and anticipate that our expenses will increase substantially in the foreseeable future as we:

● continue to undertake formulation of novel products and subsequent preclinical and clinical trials for our product candidates;

● seek regulatory approvals for our product candidates;

● develop, formulate, manufacture and commercialize our drugs;

● implement additional internal systems and develop new infrastructure;

● acquire or in-license additional products or technologies, or expand the use of our technology;

● maintain, defend and expand the scope of our intellectual property; and

● hire additional personnel.

Future product revenue will depend on our ability to receive regulatory approvals for, and successfully market, our product candidates. In the event that our development efforts result in regulatory approval and successful commercialization of our product candidates, we will generate revenue from direct sales of our products and/or, if we license our products to future collaborators, from the receipt of license fees and royalties from licensed products.

Management estimates that our research and development expenses for the next 12 months will be approximately $2.5 million, primarily for research and pilot studies. We also estimate that other expenses, including personnel, general and administrative and miscellaneous expenses could be as much as $1.5 million during the same time period. Because we currently have no revenues, most likely the only source of funding these expenses will be through the private sale of our securities, either equity or debt. If we are unable to secure the necessary funding, our research and development plans will be delayed indefinitely. There can be no assurance that we will be able to raise the funds necessary to carry out our business plan on terms favorable to the company, or at all.

Net Operating Loss

We have accumulated approximately $2,868,948 of net operating loss carryforwards as of December 31, 2013. This loss carry forward may be offset against taxable income and income taxes in future years and expires starting in the year 2013 through 2033. The use of these losses to reduce future income taxes will depend on the generation of

sufficient taxable income prior to the expiration of the net operating loss carryforwards. In the event of certain changes in control, there will be an annual limitation on the amount of net operating loss carryforwards that can be used. No tax benefit has been reported in the financial statements for fiscal years ended December 31, 2013 and 2012 or the six months ended June 30, 2014, because it has been fully offset by a valuation reserve. The use of future tax benefit is undeterminable because we have not started full operations.

Inflation

In the opinion of management, inflation has not and will not have a material effect on our operations in the immediate future. Management will continue to monitor inflation and evaluate the possible future effects of inflation on our business and operations.

Off-balance Sheet Arrangements

We have no off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

This item is not required for a smaller reporting company.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures. Disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Disclosure and control procedures are also designed to ensure that such information is accumulated and communicated to management, including the chief executive officer and principal accounting officer, to allow timely decisions regarding required disclosures.

As of the end of the period covered by this quarterly report, we carried out an evaluation, under the supervision and with the participation of management, including our chief executive officer and principal accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures. In designing and evaluating the disclosure controls and procedures, management recognizes that there are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their desired control objectives. Additionally, in evaluating and implementing possible controls and procedures, management is required to apply its reasonable judgment. Based on the evaluation described above, management, including our principal executive officer and principal accounting officer, has concluded that, as of June 30, 2014, our disclosure controls and procedures were not effective.

Changes in Internal Control Over Financial Reporting. Management has evaluated whether any change in our internal control over financial reporting occurred during the second quarter of fiscal 2014. Based on its evaluation, management, including the chief executive officer and principal accounting officer, has concluded that there has been no change in our internal control over financial reporting during the second quarter of fiscal 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

There are no material pending legal proceedings to which we are a party or to which any of our property is subject and, to the best of our knowledge, no such actions against us are contemplated or threatened.

Item 1A. Risk Factors

This item is not required for a smaller reporting company.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

This Item is not applicable.

Item 3. Defaults Upon Senior Securities

This Item is not applicable.

Item 4.

Mine Safety Disclosures

This Item is not applicable.

Item 5. Other Information

None

Item 6. Exhibits


	Exhibit 31.1		Certification of C.E.O. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

	Exhibit 31.2		Certification of Principal Accounting Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
	Exhibit 32.1		Certification of C.E.O. Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.


Exhibit 32.2		Certification of Principal Accounting Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 101*

Interactive Data File

In accordance with Rule 406T of Regulation S-T, these XBRL (eXtensible Business Reporting Language) documents are furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	PROTECT PHARMACEUTICAL CORPORATION

Date: August 19, 2014	By:	/S/ GEOFF WILLIAMS
		*Geoff Williams*
		President, C.E.O. and Director

Date: August 19, 2014	By:	/S/ KEITH ELISON .
		*Keith Elison*
		C.F.O., Chief Accounting Officer

EX-31 2 exhibit311.htm Converted by EDGARwiz

Exhibit 31.1

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Geoff Williams, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Protect Pharmaceutical Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


	c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


	d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 19, 2014

/S/ GEOFF WILLIAMS

Geoff Williams
Chief Executive Officer

EX-31 3 exhibit312.htm Converted by EDGARwiz

Exhibit 31.2

CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Keith M Elison, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Protect Pharmaceutical Corporation;


	c.	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


	d.	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: August 19, 2014

/S/ KEITH M. ELISON

Keith M Elison

EX-32 4 exhibit321.htm Converted by EDGARwiz

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Protect Pharmaceutical Corporation (the “Company”) on Form 10-Q for the period ended June 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Geoff Williams, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


/s/ GEOFF WILLIAMS

Geoff Williams
Chief Executive Officer
August 19, 2014

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. The foregoing certifications are accompanying the Company's Form 10-Q solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of the Form 10-Q or as a separate disclosure document.

EX-32 5 exhibit322.htm Converted by EDGARwiz

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Protect Pharmaceutical Corporation (the “Company”) on Form 10-Q for the period ended June 30, 2014, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Keith M Elison, Chief Financial Officer and Principal Accounting Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


/s/ KEITH M ELISON

Keith M Elison
Chief Financial Officer Chief Accounting Officer
August 19, 2014

EX-101.INS 6 prtt-20140630.xml 10-Q 2014-06-30 false PROTECT PHARMACEUTICAL Corp 0001493526 --12-31 44573012 44573012 Smaller Reporting Company No No No 2014 Q2

591

681

591

681

591

681

61954

60104

23939

34439

24940

604933

595809

604933

595809

222865

8357980

8354980

-9185187

-9172973

-604342

-595128

591

681

1353540

8630

9727

9125

11313

1507868

1500

3000

5897730

447209

10175

11273

12214

14403

9206347

-10175

-11273

-12214

-14403

-9206347

640000

-10175

-11273

-12214

-14403

-8566347

-4340551

-10175

-11273

-12214

-14403

-12906898

-0.00

44573012

-12214

-14403

-12906898

9904653

3000

15000

1250000

564300

9499

4860

99958

-640000

1850

-1521

61955

7975

165476

491667

486826

-90

-89

-507062

640000

13046

100

-145493

-132347

-90

-89

591

681

860

771

591

750000

<pre style='text-align:justify'>NOTE 1 - CONDENSED FINANCIAL STATEMENTS</pre><pre style='text-align:justify'>The accompanying financial statements have been prepared by the Company without audit.  In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2014, and for all periods presented herein, have been made.</pre><pre style='text-align:justify'>Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted.  It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2013 audited financial statements.  The results of operations for the periods ended June 30, 2014and 2013 are not necessarily indicative of the operating results for the full years.</pre>

<pre style='text-align:justify'>NOTE 2 - GOING CONCERN</pre><pre style='text-align:justify'>The Companys financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business.  However, the Company does not have significant cash or other material assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern.  It is the intent of the Company to seek a merger with an existing, operating company.  In the interim, shareholders of the Company have committed to meeting its minimal operating expenses</pre>

<pre style='text-align:justify'>NOTE 3 SIGNIFICANT ACCOUNTING POLICIES</pre> Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.   Basic (Loss) per Common Share Basic loss per share is calculated by dividing the Companys net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Companys net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of June 30, 2014 and 2013.   Recent Accounting Pronouncements The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Companys financial position or statements.

<pre style='margin-right:-.5in;text-align:justify'>NOTE 4 RELATED-PARTY TRANSACTIONS</pre><pre style='text-align:justify'>The Company owed trade accounts payable to a related party in the amount of $21,714, and $23,939, as of June 30, 2014, and December 31, 2013, respectively.  These amounts related to accounting and consulting services provided by an entity that is partially owned by a Company officer.</pre><pre style='text-align:justify'>The Company has recorded advances from related parties and expenses paid by related parties on behalf of the Company as related party payables. As of June 30, 2014 and December 31, 2013, respectively, the related party payable outstanding balance totaled $34,439  and $24,940 . These payables are non-interest bearing, unsecured, and are due on demand.</pre> Contributed Capital During the six months ended June 30, 2014 and 2013, a related-party has contributed various administrative services to the Company. These services have been valued at $3,000 for the six month periods then ended.

<pre style='margin-right:-.5in;text-align:justify'>NOTE 5 SALE OF PATENTS</pre><pre style='margin-right:-.5in;text-align:justify'>      </pre><pre style='text-align:justify'>On January 31, 2011, Protect Pharmaceutical Corporation (the Company) finalized and closed a Patent Purchase Agreement (the Agreement) with Grünenthal GmbH (Grünenthal), a company organized under the laws of Germany.  Pursuant to the terms of the Agreement, the Company sold to Grünenthal all of the Companys rights title and interest in and to certain inventions described and claimed in certain patents and patent applications (collectively the Patents), including without limitation, all extensions, continuations, provisions, derivatives and related applications thereof.  The Patents relate to Opioid Formulations and Methods of treating acute and chronic pain.</pre><pre style='text-align:justify'>In exchange for the Patents, Grünenthal paid the Company $1,600,000. The Company originally acquired the subject Patents sold to Grünenthal, together with other inventions and patents, in February 2010 pursuant to a Patent Acquisition Agreement with Nectid, Inc. (Nectid), a privately held New Jersey company.  Under the terms of the Patent Acquisition Agreement and Addendum, the Company agreed that in the event the Company sold out right any of the patents acquired from Nectid without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Company.  Accordingly, the Company realized 40%, or $640,000 from the proceeds of the sale and the balance will be paid to Nectid.  The Company retains all other inventions, patents and technologies initially acquired from Nectid.</pre>

<pre style='text-align:justify'>NOTE 6 - STOCK PURCHASE AGREEMENT</pre> On June 17, 2011, Protect Pharmaceutical Corporation finalized the execution of an Investment Agreement with Kodiak Capital Group, LLC, a Delaware limited liability company. The Agreement provides the Company with an equity line whereby the Company can sell to Kodiak, from time-to-time, shares of the Companys common stock up to an aggregate value of $10 million dollars over a two-year period. As part of the agreement, the Company will file with the SEC a registration statement under the Securities Act of 1933 to register the common stock that may be sold to Kodiak pursuant to the Agreement.       Under the terms of the Agreement, The Company has the right to deliver to Kodiak a put notice stating the dollar amount of common shares we intend to sell to Kodiak, up to $250,000. The amount that the Company is entitled to sell to Kodiak under any single put notice will be equal to, at Kodiak's election, either: (i) 200% of the average daily volume (U.S. market only) of the common stock for the three trading days prior to the put notice, multiplied by the average of the three daily closing bid prices immediately preceding the put notice date; or (ii) up to $250,000.   The Company cannot submit a new put notice until after the closing of the previous notice. The purchase price for the shares pursuant to the put notice will be equal to 92% of the lowest closing best bid price of the common stock during the five trading days after the put notice is delivered. The shares must be paid for and share certificates delivered within the pricing period, which is seven days from the date the put notice is delivered.   The Company has the option to specify a floor price for any put notice. In the event our shares fall below the floor price, the put will be temporarily suspended. The put will resume if, during the pricing period for that put, the common stock trades above the floor price.   The Company has agreed to pay to Kodiak an initial fee of 150,000 shares of common stock following execution of the Agreement. Also, the Company has agreed to pay Kodiak a commitment fee equal to 3% of the total amount of the commitment, payable as follows: (i) 25% on the first closing of a put notice; (ii) 25% on the second closing, (iii) 25% on the third closing; and (iv) 25% on the fourth closing or eight months from execution of the Agreement. The commitment fee is payable in Company common stock.   In connection with the Agreement, we entered into a Registration Rights Agreement with Kodiak, whereby the Company agreed to register with the SEC the shares to be issued pursuant to the Agreement. The Company must prepare and file within 90 days from the date of the Agreement, a registration statement under the Securities Act of 1933.   The Company intended to use the proceeds from the sale of common stock pursuant to the Agreement for general corporate and working capital purposes and acquisitions of assets, businesses or operations, or for other purposes that the board of directors deems to be in the best interest of the Company.   As of December 31, 2013 the Company has not initiated any activity with respect to the Investment Agreement other than the initial issuance of 150,000 common shares.  The Company has not registered with the SEC the shares to be issued to Kodak.  The Agreement expired on June 17, 2014.

NOTE 6 SUBSEQUENT EVENTS   In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report.

Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.

Basic (Loss) per Common Share Basic loss per share is calculated by dividing the Companys net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Companys net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of June 30, 2014 and 2013.

Recent Accounting Pronouncements The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Companys financial position or statements.

Contributed Capital During the six months ended June 30, 2014 and 2013, a related-party has contributed various administrative services to the Company. These services have been valued at $3,000 for the six month periods then ended.

0001493526 2014-01-01 2014-06-30 0001493526 2014-06-30 0001493526 2013-12-31 0001493526 2014-04-01 2014-06-30 0001493526 2013-04-01 2013-06-30 0001493526 2013-01-01 2013-06-30 0001493526 1987-08-05 2014-06-30 0001493526 2013-06-30 0001493526 2012-12-31 iso4217:USD shares iso4217:USD shares

EX-101.SCH 7 prtt-20140630.xsd 000130 - Disclosure - Note 3 - Significant Accounting Policies: Recent Accounting Pronouncements (Policies) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Note 3 - Significant Accounting Policies: Use of Estimates (Policies) link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Note 4 - Related-party Transactions link:presentationLink link:definitionLink link:calculationLink 000050 - Disclosure - Note 2 - Going Concern link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Note 4 - Related-party Transactions: Contributed Capital (Policies) link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Condensed Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000040 - Disclosure - Note 1 - Condensed Financial Statements link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Note 3 - Significant Accounting Policies: Basic (loss) Per Common Share (Policies) link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Note 3 - Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Note 5 - Sale of Patents link:presentationLink link:definitionLink link:calculationLink 000000 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Note 6 - Stock Purchase Agreement link:presentationLink link:definitionLink link:calculationLink 000010 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Note 6 - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Condensed Statements of Operations link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 prtt-20140630_cal.xml EX-101.DEF 9 prtt-20140630_def.xml EX-101.LAB 10 prtt-20140630_lab.xml Capital contributed by officer Deficit accumulated during the development stage Total Current Liabilities NET INCREASE (DECREASE) IN CASH Common stock issued for research and development costs EntityCurrentReportingStatus Policies SUPPLEMENTAL CASH FLOW INFORMATION: WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING Research and development EXPENSES REVENUES CURRENT ASSETS ASSETS Loss from disposition of subsidiary General and administrative Preferred stock; 10,000,000 shares authorized,at $0.001 par value, no shares issued or outstanding Contributed Capital Note 2 - Going Concern Net Cash Used in Investing Activities Accounts payable - related parties DocumentFiscalYearFocus CurrentFiscalYearEndDate DocumentPeriodEndDate Note 6 - Stock Purchase Agreement NON-CASH FINANCING ACTIVITIES: Repayment of related party payable INVESTING ACTIVITIES Adjustments to reconcile loss to net cash flows from operating activities LOSS BEFORE DISCONTINUED OPERATIONS OTHER INCOME Other accrued expenses Total Current Assets EntityFilerCategory Recent Accounting Pronouncements Note 6 - Subsequent Events Net Cash Provided by (Used in) Financing Activities Changes in operating assets and liabilities Net loss Income Taxes Total Other Income Gain on sale of patents Professional Fees Total Stockholders' Deficit CURRENT LIABILITIES EntityWellKnownSeasonedIssuer Common stock issued for prepaid services FINANCING ACTIVITIES Executive compensation EntityCommonStockSharesOutstanding DocumentType Proceeds from sale of patent Services contributed by officers Common stock; 100,000,000 shares authorized,at $0.005 par value, 44,573,012 and 44,573,012 shares issued and outstanding, respectively STOCKHOLDERS' DEFICIT LIABILITIES AND STOCKHOLDERS' DEFICIT Note 3 - Significant Accounting Policies Accounts payable PROFIT LOSS Accounts payable and accrued expenses Use of Estimates Net Cash Provided by Operating Activities Additional paid-in capital Basic (loss) Per Common Share Expenses paid on behalf of the Company Total Expenses TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT TOTAL ASSETS AmendmentFlag Document and Entity Information: Notes CASH AT BEGINNING OF PERIOD CASH AT BEGINNING OF PERIOD CASH AT END OF PERIOD Cash Note 4 - Related-party Transactions Common stock issued for services Note 5 - Sale of Patents Prepaid expenses BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK LOSS FROM DISCONTINUED OPERATIONS DocumentFiscalPeriodFocus EntityRegistrantName Proceeds from related party payable REVENUES {1} REVENUES TOTAL LIABILITIES Notes payable - related parties EntityPublicFloat EntityCentralIndexKey Note 1 - Condensed Financial Statements OPERATING ACTIVITIES LOSS FROM OPERATIONS EntityVoluntaryFilers EX-101.PRE 11 prtt-20140630_pre.xml EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!1[-T`F0$```8,```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,EEU/PC`4AN]-_`]+;PWK MAHIH&%SX<:DDX@^HZQEKV-JF+0C_WK/R$4,FA$AB;]9L[7G?9\UV^@Y&R[J* M%F"L4#(C:9R0"&2NN)#3C'Q,7CI]$EG')&>5DI"1%5@R&EY>#"8K#3;":FDS M4CJG'RBU>0DUL['2('&F4*9F#F_-E&J6S]@4:#=)>C17TH%T'==HD.'@"0HV MKUSTO,3':Q(#E271XWIAXY41IG4E%3^3H!L)Q'0C'32`YH%`+C M!.RB:5O$VSEBYCW=<"]C0I.J.?`6;^I3_/`;``#__P,`4$L#!!0`!@`(```` M(0"U53`C]0```$P"```+``@"7W)E;',O+G)E;',@H@0"**```@`````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````C)+/3L,P#,;O2+Q#Y/OJ;D@(H:6[3$B[(50>P"3N'[6-HR1` M]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B9VD4 MQQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%HT9,9 MJ&74"T\U<%J"`=[!ZH^^CSYLK$SO+=N5# M9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A`+<. M76Q8`0``?PH``!H`"`%X;"]?J>RD2N!)'*?<_JW!=J.: MT2&7S!YRW_]X[GSGV[5-4=09/)GLO07MKK3@G\:>L`)POJBR)3C)AA3R_F0] M\\2,7X<1\\`T8D[B3"H'*V4A?W76SQXO@D9IBB:T&U+-*O"@5I09D02F$0F) M,ZD<=.?&+X7A@_J)J?ZA;=`RTBEGX_SB@XN+/N3]4U!&Q)0,PT:[<`RIWR5' MPDPJ9.C\/TQ*F@FNAG2S##RH)>DF-(V@BO6L24G45@F@4%LPD,LZ%@ M1&@U8G##1]?&W3<```#__P,`4$L#!!0`!@`(````(0"F*;*[9`(``/0%```/ M````>&PO=V]R:V)O;VLN>&ULC)1/4]LP$,7OG>EW\.A>_"%.H4W%'"[-*K:U`9;;$L!5,LZ29!173"BR(XS-_S!T40@.WS5O M*E!N!S$@F4/YMA2U)=/+0DAXW'44L;J^9Q7JWD@226;=+!<.\@DYQ:5>P]$# MT]0WC9"X>S%(!B2>=DT^F"B'@C72+;&]/1W]RH99-O)O>BL>!:SMH<@OH\V3 M4+E>^U?1VFVW&J"`=;OU)')7XGZ2)-VSGR!6I=L_1'P<\%L'\3OM-5)M>WM' M*$Z*SI03;DOOU,Y]H7&$WO4[["PED1D+O#%W>>J%AY1;K7)0%G)ZPR13'.C" MU]F@/@OJLX_K%XXY-$HY2W5!?]5@F`LH@X#2&MVOXIARRVQ)YP%E&%"&;[7< M:P6YD)A2X))BMB`DHX"S&DO)J,_-!X(#^-@,+$'.\^"XC8(82>MA@%= MB)42F%NF'+WF7#C4,Z6^?<\AK9G"X2\.491QS'V(N`LQY M+^:4+I@$/Y0'A.%\@G*?T$[%16_Y",W3_(4^-(:7S`*]7AGP@PXQ1QE+/N(T MSQ;^-BB!SE[?"@E3EKZ+Z>>VXM>[\61AT-)W>?T/_#GOX#``#__P,` M4$L#!!0`!@`(````(0`NHJD:8P4``$P6```8````>&PO=V]R:W-H965T&ULG%A;CZLV$'ZOU/^`>$_`A$N(DAPMH&V/U$I5U?Q],^,9Q]MO[\7%>.55G8MR9[*E;1J\S,0A+T\[ M\^^_'A=KTZB;M#RD%U'RG?F#U^:W_<\_;=]$]5R?.6\,L%#6._/<-->-9=79 MF1=IO1177L+(451%VL!C=;+J:\730SNIN%B.;?M6D>:E218VU1P;XGC,,YZ( M[*7@94-&*GY)&^!?G_-K?;-69'/,%6GU_')=9**X@HFG_)(W/UJCIE%DF^^G M4E3ITP5TOS,WS6ZVVX<[\T6>5:(6QV8)YBPB>J\YM$(++.VWAQP4H-N-BA]W MY@/;)(YG6OMMZZ!_G<0+@]4(3"-H>>-T\YFC2-+*7NA'%OP1B2*HSXD@C M*V`OQ^'5S,FNG`S?M\G!7`86J6F=DZ1-NM]6XLV`C`.^]37%_&4;,'SS"FGH M_/29FT`:&GE`*SL3M@IXH(;8ONY]=VN]0C@R"8GN(4Q%Q#<$.@RM)O0"/CNK M3MC-L4!`IP*<.%3Q<4QO9!&,9&_K1/1"6:=;IF42WR/TEP?3R*2,81"'I:93Q[!.Q,R)/D#'/3R(20I`#H(:#AMX'B@@\`0Q*Y#AY!*OD@]XL MD2?(&/E)1$(((N_Y+@2PBY_"/52YSPL`3M(T:+4Z(HA,6S?4XA,/A]VUWY-K M/9`,A\,P]/K<5,@S2)7YGF_1*FU/+S<2,^;[:4@B(:1^X;N?IP[#%C8[=UJT MJB#HFP@EC\3(M%U[FFMC97S!/$>+7*(`?!9Z?3]1G8\-;3YU:G_#6K^Z6QH\\E3^QN2#_HJ+/U.&"+OALSWM6X0 ML[$F*OF/&%'Y0X9^@3^BU;Q9]5M*\B?,:.9/0A)&$.F%M;]V^A"J`K"O#0(P MK_#@>5P3$F@M-9(8EXX,X5W^WUHN'D(7:ZTP)7(V"5AX=F#[_0Y3%6"+&R@8 M+_N,&J*20EKV1A(S&@(R,P))I!52,%I[L,'-%T#M4!'0QU;FT&13C=DD))&0 M&0*PR'NE ML]=[KL0`BT__Z4Y#\'8/5Z(_^\%'?[CH\H[NIPI>G7C,+Y?:R,0+7LPYT/*[ MM]VEX8.#%SG:^XAMX#H)WEO=`-SE7=,3_SVM3GE9&Q=^!)/V,@!2%=T&TD,C MKNVMV)-HX!:O_7F&6UL.%U+V$L!'(9K;`R[0W0/O_P,``/__`P!02P,$%``& M``@````A``^[G923`@``K@8``!D```!X;"]W;W)K&ULE%5=;YLP%'V?M/]@^;T82)HV**1*5W6KM$G3M(]GQUS`*L;(=IKVW^\: M)Y0DW92^('PY/O?<0)C)6ZS6D2Q91`*W0AVRJGOW[>7UQ38AUO M"][H%G+Z`I;>+#]^6&RU>;0U@"/(T-J-%O4@U+XWC&%)-]V%T*I#BK5LI'OI22E1(GNH6FWXNL&ZGY,I%WON?G%"KZ0PVNK214C' M@M#3FN=LSI!IN2@D5N!M)P;*G*Z2[/::LN6B]^>WA*T=O1-;Z^UG(XNOL@4T M&]OD&[#6^M%#'PH?PLWL9/=]WX#OAA10\DWC?NCM%Y!5[;#;EUB0KRLK7N[` M"C04::+TTC,)W:``?!(E_62@(?PYIRDFEH6K`DEY4X.JEW7''EPNCMP3;C6C;<3\\28;$7M,$*PL,@\I_B41UGF3E M67**[N\ ME-L0&*=)WTXS>4\:#T9GQN+3V<`;,@?,=(29#HB#`A%R?H$>C,T9%S0_MC9@ MSLB,ALBT'ZAQQV;OH?7@0]I=9.SNJ,0#ZZ[>D\F##S.%R&D! M_H8].@5S/`7_'SV_Z9!^%\$1?)WQ.#X:@G`_A$.HP%3P"9K&$J$W_NRG>'J& MZ'`MK5+O^7%\FJWZP6?#![PN.E[!-VXJV5K20(F4<72%C3/AP@D+ISM4CI>& M=GA1]*\U_A<`#U`<(;C4VNT7F)@-?YKE7P```/__`P!02P,$%``&``@````A M`!``?5IW`@```@8``!D```!X;"]W;W)K&ULE%1= M;YLP%'V?M/]@^;T8R$<7%%*EJ[)56J5IVL>S8RY@%6-D.TG[[W>-$TK6;LI> M$+X!.BYV"U@42`PUWZ-_6LK,G-B4NH5/3\E4RY.W/WA%;V2PFBK2Q\8`N& M3*ME(3$#7W9BH,SI.LENYY2MEGU]?DHXV-$[L;4^?#*R^");P&)CFWP#MEH_ M>NA]X4-XF;VZO>D;\-60`DJ^:]PW??@,LJH==GN&"?F\LN+Y#JS`@B)-E,X\ MD]`-&L`G4=)/!A:$/^4T16%9N#JGDWDTNXXG"<+)%JS;2$])B=A9I]6O`$IZ M4X&KMW;''5\MC3X0;#>B;D[('>V5?+F_E-@3&,NG;,I/_ MD?%@K/?8?#H?>(-RP$Q'F.F`.$L0(9:9F66%.B0-))?1O: MXX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C M(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6 M^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5 MUJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+. M99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#L MXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^ M_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@ MK3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+ M@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN M4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<< MNDA(",Q*A!\2YICQ.IXI')61'.*(%0U^$ZNP3,C!7/A%7$\J\'1`&$>],9&R M;,UM`?H6G'X#0[TJ=?L>FT1.[P:3?$45*&'=`X+&(_D%,( M48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q- M,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63% M\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$ M#6C\S210*:D`XD2 M+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S, MUJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^ MS1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V M)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G M<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?Z MO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A M84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2 M;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U8 M2QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W) M-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?D MXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO M?K\)?.V+&R=>%([TUONFKKFA$\V]<#G2__YLW?5U+4GM<&[[4>B.]*V;Z-^/ M?_N;89)N???SB^NF&B#"9*2_I.GJOM%(G!V%>H9P'S@R(($=OZY7=TX4K.S4FWF^EVX9EJX%SOW' M91C%]LP'U4W+M)T"FQWLP`>>$T=)M$C?`ZX1+1:>X^ZR'#0"-A^$ZL((T MT9QH'::P5GE*RW[Y.!_I75W+5)Y&-,BT"W`S:Z8VKXWBSVZ;&$'GK_-3AMT@KDOOR[P8$S& M*)-P6SDS8E/HU"<:@DYM.L/K%$`EFTX>U\G^:8].@JS.:5F7V$^0Q;0XKE=M MLG;C8L>&E\@J?<7)B9>SD6Y9Z.FM9I/,RCOL2L(&TR;DW4Q8MW,SS=I6V^K5 MJID0B[M^(X%MJTY3GA!H?>@]W,R<]0L[I%V>AF_5`ZC#U6M%#UWW2/_N6?2Y M19S<>$"[CL<8JI#T6=?C8YZ5N'%HXT/+OS]L5IC4AIJ1DGT9VW8FKE[&] M;1EL<)=KD$2^-R<6RRF;3.6#V;3[:$T?F5R.F2R+`Z"6->U=`?1Q,IC6SW0Z M&-0-:ECXU`SZH4.?FD$M_#>MS:9Y1S+K(EGB::E')4KS?6\P&/1;W7Z_/S#; M+=-D1I[E$>V%@@4#Q7V58Z#(JQP#15[M MU9R!>\J]RC%0Y%6.@2*OLE6C&OLJ%D,5]U6.@2*O<@P4>;6VR6>>@0?*OJY613/L;-0+IIYHL$?+$RUD=13C9J_&98E/Z7D/DS?V%BX_1B-/]1@Y'-?W/U,N M_^>B'#ZP;A;<5BOVJFD=E'9=Z2N6!_.OV5"1'8#CH4;&P4::O5KYVZ=U M,'-CBVU@,Q'L+"U#5D<3-L95QQ]\;QD&+EM[T3.8'^(H=9V4;;"SY=E#?-H' M^&#?5YK/)?+-`_)AIYO(1VV_UXFPBU+Y""YI^77&`]U*D`*I@@)EQP0`!6C$`G2-1<4D_;''9##%0B83\:XE$CBFT M%$1>4GW(C-S^1:!7ID9!T<(7"3R4(I5E6(XMZ.G52;`P1$3 M6!AUZQGR6H=ROC*#<$D7'"J+(`T0@7%)2*5%,` M'244.$>T%(V_+9Z#HA&8CP9%0S!/01B#;]@G>$\((Z0B#N"CI%=4\X26,&+< MT`P@ZH<6;FBK2I%M[J]:/]4V MBY,+J8`N5P_>NKIHGE5/6>4(7[!:BBNEZ5D:NU@[U5ZBV/L9128]SN)@,=6- M=7I(*?4<_LS7V%X]NQN4HMF6Q69Q>*T7M(KUC>,,#W*JY&/)6]?.$5Z[?2[@ M5SL2H_@B&'94+(N5B5'^$%'@OA=BY6Z4<3CN.P.I*V M[^[UHQBK5)K(\.*Q*C^*L=J6C%4>J_*C&*ND\KF\*C\"E;.7B1_.Q:K\*.8) M4S)/\#I6?A1MWY&T_=N,*D:\(1GQ&4KE.WSC;(2G[J1LE*%47A.CO"T9Y1E* MY2\QODW)^,Y0*D\!C]/(Q`\R7L]02A^U1>N:DM:=V/,BZXH!8TB:!*]F<-8^ M7FP1T6LQ6.F-]SGP"M%"JXQ"TQ?7>=6FN).J!!+[`PVC,D"/FY5OAW8:Q5N- MRNT23G1Z1Q+N3U%4VDA$,'`H0^C/>(D(WD^BP2Z9A<08IC+G')BR+XCFH;VW M@'GG[L)>^^ES^>-(K[[_ MA=V[CF#*K_K!^Q*E#&*D5]\_T4,!Z,6X=1/IYE."&\WQ5\,C\2/]E\=);_#P M:!EW_>:D?V>VW<[=H#-YN.N8T\G#@S5H&LWI_V`R>B?1/5Z7<\$[?]B[B;"D MV#+O$Q]O!HIS97/RGZMS(YT[R.BS50;0QBVRA1*-I'QGTOC_````__\#`%!+ M`P04``8`"````"$`Q=UAH_44```0-P``%````'AL+W-H87)E9%-T&ULI%O;;MM8EGT?8/[AP'`C-B`[MN6D.JDD#466'54YDDN2J]&/E'ADL4*1 M:E[LJ)_J'^9I@!G`'S)/GC^I+YFU]CF'I$C)"6H0!(C(<]G7M6_,N[]]78;J M7B=I$$?O]TZ/3_:4CF:Q'T1W[_=N)Y='?]U3:>9%OA?&D7Z_M];IWM\^_/N_ MO4O33&%OE+[?6V39ZNW+E^ELH9=>>ARO=(0W\SA9>AE^)GO7RZ](-I3LSB/LO=[9S^T]U0>!?_,==<\.6V?[GUXEP8?WF4?+N)9 MOM11ID"&ZD59D*U5/S+G@VQU<#N^4/N'[UYF']Z]Y!:S[;7Z'$?9(L467_OU MMS_ET;%JG[34V?WE-VY\6U__HO[`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`O[;>\3.V?')^M5S^T6R>G M9R+`RD][0$!C]N5E7/IV"W)+5WJ6!?Q_?!3AQ!P2LO\(^"2,V\50"% MUS5\H>?!+$!`F2&RY$83?I[0KR%)Y6L<'Z\DY@!6[AHH:"0I^+.(0Q_A\X6R M9]:O:LA2=087:CP9=G_^-+R^Z(W&V-J[['?[D_K6TH6('YKDI"J>J^%*)QX9 MW>U,S[I2-?2UZY>.>K_V!K=-E8]T"K2>+40E%0'5]]\D\5RG3">@ADO=-.W> M5SW+J4`$_R7]15BI'W.E(S`9&O?RET$D@93;ZBN-+GH[7.]Z.!ZKR]'PLQK> M]$:=27\X:%CS%5(1A3PB]>#/D.\*PH:HMU]D7*V/'*D9T>6RC[W+X:BG+OKC M[G`PZ4.6%\_<7=+WG1N0-%SV)XK[Z@1^[(S[73&OB_[U[03WRNG@6XV18O34 M\%)UAY\_#P?&_NK[7SP]/CW6'_Z]U[_ZQ+,ZOT)^5STUN/W\$2?B+#ETK(:W MD_$$1MT?7-4W[[)@(K-",'[8:<%66X,KU>E.^K]N1:&!SE08IPU%(30C.S#H MI"R0(%M4J4[N@UG3(L?V.0P2:4TPS0G,TS5,`2@!WVYRM?U\8--6%\&Y:=.< MKD&YFB?Q4OE!NHI3@2Z:7YI/T\`/$/[K%SLC%WBCQ4[UP@OGW$38VI&2U*-/ M_=2;1!,N=T8OBED4!M>^#Y!*4S86@P"8':+QUC""]3.M?0Z`2S>M;D,!Y:PD#$/%W[2CXJ`KK MP#)UJ"Z#"+D0X\QNK@:]B>H/NJ->9]Q3!Q<]\Z]#/%/=SOA3G48^4YV)^MB[ MZ@\&<$*Z)GR^/[S8M;2'"+1[T0[O65DSV>5%`Z0LZE0=P0Q=YF>Y!8R7`:Q. M$[A+R`IM%2*`V4Y_^6IYD)T0XCHD3A6D6LAD/8T`RE`4FK M;#A4D08LI?!XE<6D*L6Y:NX%"7:2L)(/!Q22">6A20A0<=N$`,2@1IX17N<" MK\B^$.YU4>F:!41#4HU]J`Z1:)HK(0GDD3J(6JH4TM+S]7%=:UV=9(R:0:4, MY\WS.,XB&@(P;09LSG&PY1VL6(F(?YUNC0![Q,LBP M0=2=(6P`A^_N`$$X(UM`C#@S9<[BMFQE8*JA8D]HP,K?\@C@"(,1!C856>&: M@J/04MZ1:)A`55#<9I']18HLD.9.H@'@&>EH7I/#6%R^E>P20)RZP1NC8Q'&IUE^P%XY_AWL-C(#DKR@FH.K6 M!A72SC$'&P#AJ4FP;)F:UM9Y]4M$##.$3`$/DKU$EX-V1"Y9MQ#V2VYWM0C$ M"=IP@G%%'39SXVDW,(WBLEG0(2A/@%@8-/X<(UD;&6T"9:-Y$[T3# MO!DBRG`J(O2^:!J6(FZ!4X]N9S]`'$KI&8H"D'^_.6O$/`?L.' MBD:''%6&)O)/9X2`:3^[]IA;X(4B,!K<5D$0*_ER&SF%/W"1LP%5:3F83=2T M06,B-U+$7'(&`]X08.@CL(+QQ!0.R%*@Q$)0#63]Z*7!3!VPTCCDN81&5D;2 M,ZU#IUG,>DJ62A^&81!]VIEMD2#O]Y'K^R23G%I/$Z2-;#&F-A&0KH$;Y33G M0CB&NQ]T<+<0M0$4D$RI*)?()DHI=Z55,5GAJ(L@E"H-`24"-7^>9$1:%/+* MN_>"T*'V,S3[]MYG:+<-K$K7JLH`0^"QQ.0_=Q040ME-1;,%%:7D[.TFNV16 M`,A&FUJM$&1AZ,!7ZA#"8P/&UU.@9J+HA=E:R$)H-*$>R(T<\4C`MXEK9>P+ M$!>`,[!ARKUK:HM:;N&2M)A@0I;B##;TZ M]Y+UG`N\CWK7J'LNCFXZH\D_U&34&8S9&MG2SZJ*#/$?;"7(X5T"7;:5&6\A M1=/^-+38W-D`*;6Z?W;:^N'TW)0-^V?MUIOV&_QH:MRL:*2GFQU;HAJH`V@Y MJ';7DY8R1!`E`8R2QW9F^(5F3X6T]=,-7IW88DW$.`B[WV^>M\_8;]?1(CO;/SEMOSD\4 M]&349/LBX%?R_P@]=21%B#A@S&,=V\+8-F51BTZ_"(4+?21MX-W'.#CR&Q+O M(N*Z+IOMX-3-_B(O>O%I\%4A@G".NZ4^D2N),[C]<0Y. M-KK)I6W!`K/2PP4,8:>%Z1$7GAZE;4`$HH%@L($1!H8>MLAY>@2Q3X]";5%: MXTP:*BRJ(0C!@U?,^6SC^0:XM@4"!01>F1RO4A5U+C"$\K1C=\8^!%RANP49&P62RGF.UQ?N5U:)SBY8BX2 M$!+F,XC/06;G@H6SL)T!H>`8E(&V<8("R:2SODYG,-)"<%ZPQ+^95MNU=AXA M1YA_NR3+''`PBS&<1@#A4(QJ(6'6EHRD3#^!4$KQLK45!DC719F0(TIS_16F MQZE-VA*O0>$E;_%30->^@G"#>[Q`;U;(<8!CDSZ7GP,BXKD%>T>)=4\*8;@* M8C2<+U$S,+/DK7+:9PWB?*,1U,2"_1Z&10@7-*D%$@7DLT#;J.%+?99UL#!D M\LX=W<6M#=T)5EZ!TR8O)F4*5`@!(OV_&_B'L99 M4?0V#`06%-^!%U=SFG(Z0$?;JISL6*VVJ.E+/4W$"P%E)VI5,=/"@3JDP0X) M"E,UWC*@[@&__0@C>"0",U>`6XXJN2I3CTY.<0$CP1Y?L2&0;2P2P=$6Q6^@8DY<9(45 M32EW&9,8K@H+G@<)PI#X>^9]H6WSA,IDLG::H1#&7)U),,>5P<2#%%=3-BYE MQM%2KT_^0ENUMY+7<_.DPB@EQTPV84D4KC>%8+HZ$`/VH=60J/W7YV9(+NSP MF((:R[B0PJOXTH7JAP#^"D/\JG']\4CUN,F]HBIF0DS,A"(%6FB&27)&*?F.3_C0S?O M"Z9;\I4`<"+.5RUU?=UM(1]Z>KQ`;OS`A$;0$IIT_;?2=:24*T\5K`2@;QAZ MT7>2,@N'@+T'=GIM(>Q4B!8<\@WH#V9G*&O9.A\1X2B+C]`0P;<3KL!L!B"$ M0RFV13?YBN?@2.\.WG@'`S`?7U`H^T"9)9.XMIE[5!P!7@FZY_B&RD`27XU[74G*S#=P1/FR.#)^*U(:,WN4 M^2$;'KSF]$V[3=I!-1IU-IQO\";`LO36=`N'OU:75?`D%85N&K:\`_**#2W1 MK5,.TTF>9\`*U/DZ1!A$KN&4I6`Q`-\5$"V*D3-I`#!20D99VR\QHK:U#SEU M3)F/9AYL)Q/NS];EIB$8=>Z?O1((,:'*EFDBC:HR4`LQTB`-V7*4%3W!DJUO M:*RDV*@10D5'`*E7%B,YR*PM8OB@)8#YS\I;`.V\KQ MT4Y9JWM\QX;FRL'M\?@8%77R!3TB3L,.W7+'OQBLS:(A900/J5DI-]];PP"1 MNHNDR65);DLA?\@P"`K`J'4FI.G23()TN=@<9LAA3LHCI\@]<")KNV")7"LP MT7'%A@*!7#:6MX"$3/](`#\(P&Y-$77\FN!29S-P:%@",P8D6_"%"*&W>ZE8C#49E<.\31XM#!2ICL6$NO%7+G-1Q&E6O3DKM(:> M.TNZ0CY2WSDA;=55I7,Y9R>)'89"6R5'E?MAD]9C4`F)9UF:ESFNALE)>#/M M*DP2Z!&2`,MH@H.28K<@C,DJC,-!E;S;]`9;XG5V`HOY`_,.8T1%U*4^ZSK> M(.\YG3HBJ:1\&JK4?25*#TCI!-3Q(4Z50THK1H]!21!0K`'#80J0G)B+`F'FL/'B?4&SYPD M*IAH,8$#(5*MJT&=GEW@-'HF80JDXD/G>4TB;'B0FA'>*-D`:2C\H5VX@_1& M*BC-@RD;LXO)E/WT$[TA!$]\Q62!\!6.,"HVR:ES*'#E50SA1P,D9^5R=%`P M5W8.V.)[`FNY(%L$2?'^1T1U'VON-Y;,85`8DQ=WHJW+>M0U3\3ZGQ,B=5AR M*?J!4SA>X6].MEPDL1P]X88EP,3!2L2*!&LD\]E05@MM?P8G9#^L<>$^GG*? MRYF#\'Z+-;@.2&,_":N#97'E9ATH^`0L M1A)DZM`BRX%,WIQLPQ8+X,6!;%48VFS_I&@2?S,/:@B8:G*:8'^![D\/R]%; M(:=%25'`G105=A\`YIICE(CF_I4 M"G@W,W;C:"P#-E:_5,%/PKTI5HJSBF1F&GLP>=#M8T(XRV*DJ#XZ1\C"C!*- MHTT9JXH^BQ6\E4]#=DAEL:+12:TCQ],C(N[3HT$JC@6(XVS0XS,W.^$$PG)D M0%HH]*T5AF$,_!A*'?#1^N2K%I#BT,^YE.2!QVC&5K5,+&,:X:P;!'V7?8,V MN(WWQ9U7F"/G'9`IA+M9:YTW!#;@Q$*J-WR3"*1D"=]C(;]]4/':]"AO/XY[ MO]RB/ZGX+7'S,RU@!'O]U8][.N.N^NNK5T>G^`\YSKK1M;.?6('U^T!SDL%` M67R6('&463G*MKN%*$)"NU@!L,O,5,4Z?C+\1$*C\;KPX MFQ]A6H;=-2Q($'KY0=CV/_6T0:3W'3/]MZH^BU<';MY_6#_4O:@___[+[%28 MD]Y#=8,*!@(GH(\EY]I]\[/[_CPYHV\,!)^1A?#\_$#M+;@K9P"NT-_&Y$O\ MC[8/_R<`````__\#`%!+`P04``8`"````"$`*C?:X.,$``#,$P``&````'AL M+W=O:=T#<-V".(4JR50+, M;&F/-!K-X9H0)T$%'`%MVK>?96P.=MA`;MJ&]7GA__>RN^+MM\\\4SYP6:6D MV*EHI:L*+A)R2HO+3OWG[^AEK2I5'1>G.",%WJE?N%*_[7_]97LGY5MUQ;A6 M($-1[=1K7=\VFE8E5YS'U8K<<`&1,RGSN(:/Y46K;B6.3\V@/-,,77>T/$X+ ME678E$MRD/,Y37!`DO<<%S5+4N(LKF'^U36]56VV/%F2+H_+M_?;2T+R&Z0X MIEE:?S5)525/-M\O!2GC8P:Z/Y$5)VWNYL-#^CQ-2E*1<[V"=!J;Z*-F3_,T MR+3?GE)00&U72GS>J:]H$R%'U?;;QJ!_4WRO!G\KU97U7^1^^\XO5QK6&X;%%%AF]-7@*L$ M'(4T*\.FF1*2P03@IY*GM#3`D?BS^7U/3_5UIYK.RG9U$P&N''%51RE-J2K) M>U63_#\&(9Z*)3%X$AC!DR!XM'"PPP?#[W:PNW0&&E/3F!/$=;S?EN2N0,7! M?*M;3.L7;2!QZPK3T/GT,YO`'YKDE6;9J;!5P($*UO9C;SE;[0.6(^&(/X*X M(G)H$6H^31NT#_JT2!P2MD0[)&(/X&SY`I`V:)8)8(9XF( M$6ZS[Y!IF[;5SU0P`(Z=Y0906#)`VGT^0YSFQ6O'[-_*=L`P[+F&M-T#(0RG MJ.AN.`PC9")3C$="W-;=M=-O+T$U'&O+55-84MUO)U;W#&&JD:W+JJ?#P3!L MZO+H<#H<#F":/<9T1261$MN^PRQV-DN+=5!"$H'?S`,KJ4S)!P& M/3*$^0QAPE_0B'(1&)$N`B/: M16!$O`!,JD?0`RY?]X:6]$NEZG,&SM/NT)?6[C"/!/-(.(]$'.&+X5AP5/3[ M0Z@"1'N>Q?7?T)(/?7FQ$XXSDSZP1FL"">:SA/-(Q!'FPZ0-M!$:V$!;61-* M9/HXH/VWO"WZ_R/<#L9,[`N>I25&-H9$C.P,B1C9&B*QMIV?GPR(-D7/F\%: M*:'IZ<]<;L94N]4@A^;E.W6R-F:SA/-9(HYPVRW3TFV[[U'$30*S&1HR4Q64 M%C>)T^\^;@1C6-LU>EHBD1BK"I$8JPJ1&*L*D3`\W5E[?0F++M"FZ?FR8*W6 ML"R&^DGP#3'/!`ORA`L8>H="YS-I"KLD8?<`.2XO^("S MK%(2\DXO0$QH\KJGW>7,JT&__$K/?;2!;^V/SP.T@:_F\%SK!L!=RBV^X#_B M\I(6E9+A,[Q*7[E0&B6[C6$?:G)K;B6.I(9;E.;/*]R:8;@/T%<`GPFIVP_T M!=T]W/Y_````__\#`%!+`P04``8`"````"$`"'S@-_(#``#C#0``&````'AL M+W=OK#Z\U)7QC#M:DB8Q MT<(V#=SDI"B;?6+^_/%X%YD&95E39!5I<&*^8FI^6+]_MSJ1[HD>,&8&.#0T M,0^,M4O+HOD!UQE=D!8W,+(C79TQN.SV%FT[G!7]0W5E.;8=6'56-J9P6'9S M/,AN5^;X@>3'&C=,F'2XRACPTT/9TK-;G<^QJ[/NZ=C>Y:1NP6);5B5[[4U- MH\Z7G_<-Z;)M!?-^05Z6G[W[BPO[NLP[0LF.+<#.$J"7H#]*O$)SKY;=`#.7WLRN)+V6"(-N2)9V!+R!.7?B[X M+7C8NGCZL<_`M\XH\"X[5NP[.7W"Y?[`(-T^S(A/;%F\/F":0T3!9N'XW"DG M%0#`IU&7?&E`1+*7_OM4%NR0F&ZP\$/;12`WMIBRQY);FD9^I(S4OX4(22MA MXD@3^)8F*'RSB2M-X/MLXBR@-,VXPL9 M+<'Y[V&!>'#M/1K+WW4N':@T0A@4#,)^%B6!63&;MHL!5L0N)-))ZJ M2&\I%#0PF8_&Q8D)\QZ2X3KJBS="$O;)]&,-/)V.!M$XJB#!/IB/Q,4:DJLA M"8EW!6DZ>A4I>`L2%VM(6GHV0G(-:3IZ%2E4D7@=B)21! M'ZT`Q;Z&GBKC-K+'<26)_+R;70>X6,,*-"PA$5@H\+U0$Z13@>/&[E@E%*[X M+5Q0""[7\R:O[;=J.AUWO-B[4B$0I&Y^O'JU!G91.+EC8@HR+PHB M1X^8=($].6SG*\E$O,3.SF:OUNC&;(@*)C5RF=E>[&J[-E44?NQ']NBA9!3Q M.CP?3E3M:0V;Y$3""+5D>N'<30N?+$Q=(DWE:AXVH$P MK]3QIDS;O)ZVQC92(S#O8@3-3Z1M\%37A$XZVFA3J6-E,!:1),>2L7[KR,#FNF+.&HK;2,UUTY]9?CR0!.]MN@B:]SM M<8JKBAHY.?(^&L%)--P=>OQ[I^_2AP%HL=MLC[]FW;YLJ%'A'3QJ+T)8!)UH MTL4%(VW?HVX)@^:Z_WF`/U,8.CY[`>(=(>Q\P?O)X>_9^@\```#__P,`4$L# M!!0`!@`(````(0"1R4MP<@,``,,+```8````>&PO=V]R:W-H965T&ULE)9=;YLP%(;O)^T_(.X;,/EJHI"J7=6MTB9-^[QVP"16`3/;:=I_ MOV,.,3@T6[A)`GEY'Y_CX\-9W;P4N??,I.*BC'TR"GV/E8E(>;F-_9\_'JZN M?4]I6J8T%R6+_5>F_)OU^W>K@Y!/:L>8]L"A5+&_T[I:!H%*=JR@:B0J5L(_ MF9`%U7`IMX&J)*-I_5"1!U$8SH*"\M)'AZ6\Q$-D&4_8O4CV!2LUFDB64PWK M5SM>J:-;D5QB5U#YM*^N$E%48+'A.=>OM:GO%M<7 M/?N")U(HD>D1V`6XT'[,BV`1@--ZE7*(P*3=DRR+_5NRO"-S/UBOZ@3]XNR@ M.K\]M1.'CY*GGWG)(-NP3YINOK.<)9JEL'.^9W9D(\23>?01;H4`4;7`0-2? M(^8V,I3`8KJ_C\B'>MN^2B]E&=WG^ILX?&)\N]-`FD(:3#:6Z>L]4PEL`[!& MT=2X)B('"_CT"F[J"=)(7W!U/-6[V!_/1M-Y."8@]S9,Z0=N+'TOV2LMBM\H M(HT5FD2-"7P?&A,R(I-P]G^/`-=3AWI/-5VOI#AX4&A`5!4U94N6X'N,"U=A M(ST7*$1H3&Z-2^S#"8$8%&3[>1VN@F?(9](H[E`!GU9!K"*`M=@%P2*Z"WH[ MP4>N$1NN2;A9R!W>Z&*BMS'C(1@CAAWK+'YL79&+BDE',;$*)SR07!Z>$<<^ MQ&23-K6NR$5%ESNS"H<+578YUXA=[MRZ(A<57>ZU53C<*5_SENBT[,BR%D(SXAMP6+9)0XY+;Z'#*!'GQYT+7ZA-T6+;(;S0SW>3*=CT/29L:% MF\YR<<8)]J'ND2*GM=UHYI?`3;^Y'([=R8&WQZ:)'#5.VMM#X$8^J(<1;%%= M>.?T-/!^&XO.U#F!%0Z(W*C=/8_:_6S@J.E&?A8^J)N9]_0IO#U##;S?T,[" M![4TTN]IT>E):S1.Y.>.VJ#.!F-4+_+>4>OWMJ@]$5AP."+AW%`PN64?6)XK M+Q%[,_(0."CVKIWAFN'*_@'34$6W[`N56UXJ+V<9/!J.YI!XB?,47FA1U5/) M1FB8@^J?.QB6&;S=PQ&(,R'T\<),;W;\7O\%``#__P,`4$L#!!0`!@`(```` M(0#^75T)E`(``*\&```9````>&PO=V]R:W-H965T'7,!*Q@CVVG:?[]KW%#2=%/Z M@O#E^)QS/VR6-X^J)@]@K-1-1N-H1`DT0N>R*3/ZZ^?=U9P2ZWB3\UHWD-$G ML/1F]?'#\J#-SE8`CB!#8S-:.=>FC%E1@>(VTBTT^*701G&'2U,RVQK@>;=) MU2P9C:9,<=G0P)":2SAT44@!MUKL%30ND!BHN4/_MI*M/;(I<0F=XF:W;Z^$ M5BU2;&4MW5-'2HD2Z7W9:,.W->;]&(^Y.')WBS-Z)8715A"[VOW0Q^^@"PKA]V>8$(^KS1_N@4KL*!($R43 MSR1TC0;P293TDX$%X8\935!8YJ[*Z/4TFLQ&US'"R1:LNY.>DA*QMTZK/P$4 M=Z8"5V?MECN^6AI](-AN1-N6^^&)4R0^>@H,O0_/)M.<-R@$S'F#&/>(D081Y0\^%0I1,X3\%?LJV.0 M3##;_P^?WW7*_QS!(>RG?/'2K)!)N"#"*51@2O@$=6V)T'M_^!,\/GVTOY?6 MB:_YZ_@X77>3S_H/>%^TO(1OW)2RL:2&`BE'T0Q3,>'&"0NG6S2.MX9V>%-T MKQ7^&`!/T"A"<*&U.RY0F/6_FM5?````__\#`%!+`P04``8`"````"$`^&>S M7[0"``"0!P``&0```'AL+W=O.B@)%$\?RD8;MJVA[N=XROB1W3V,\$IRHZTN7`@XZA,=U[RD2PJD M]2J74`&V/3"BR,@F3F_CB-#UJFO07RGV]N0^L)7>?S4R_RX;`=V&=<(5V&K] MB-*''$/P,1U]?=^MP$\3Y*)@N]K]TOMO0I:5@^6>04586)J_W`G+H:.`"9,9 MDKBN(0&X!DKBUH".L.?N=R]S5V4DF86+V6PZ7UP#9BNLNY?()`'?6:?5/Z^* M#RQ/20X4^#U0)O-P=AU-8C#]`$)]1EV!=\RQ]XNI MW/K`JV_L)=,3R;17#(Q!^LBT.Q*G*S:_!(OB(?80`7K?W3B9O-^\ZTNL4#RT\I%Q M!3B0S][M*!YB#Y%DU)GE)5P4#[D^,DX79MH@7YP[2XA]<$KQJZ%!!X(0G)J3 MWK_=N'[^^?&@A"G%%U'7-N!ZA[,M@0/?1_NYN^F:\38^33=^'M/^#]NT5UZH%BIVLI7ON2"E1/+TO&VW8K@;? M3]&,\2-W=SBA5Y(;;77A`J`+?:*GGE?A*@2FS3J7X`#+3HPH,KJ-TILHHN%F MW17HMQ0'.W@FMM*'ST;F7V4CH-K0)^S`3NL'A-[G&(++XD0( MR?0901;#C,Y7YRB,8!3&:F$F-SXPE(G/RTS_1P;!4.Y!\LFBI_7"'C(;0&8] M8N0/()?[0S"T9NCGI+(>/G>Q."E M,;V/K`8%3);G*PCDE_M`\%C(1TY]X)Y]_5=8S@.P_?8,XKVQPDL$-D0_[$ER MW@OX'8J^K83@L9*/G'J)0'O(VS4EF;YOIKLXUCB&1G96Y^W@I`YUW_;3H5^) M(4%&!X[\/O5+2PE3BD^BKBWA>H^[,H9MTT?[/;Z-<4I?QV?I%A3A1=B_@?W: MLE)\8Z:4C26U*(!S$BRAZ<9O:']PNH4\8ZS@2RI@Y4RPJ(76[GA` M@?[;O/D+``#__P,`4$L#!!0`!@`(````(0"!>_40I@(``"\'```8````>&PO M=V]R:W-H965T&ULE%5;;YLP%'Z?M/^`_%X,Y-*`0JID5;=* MFS1-NSP[QH`5C)'M-.V_WSDX161IN_3%X,/G[SLW'Y8WCZH)'H2Q4KBA2^E-HHYV)J*VLX(5O2'5$.3*)I3Q61+/$-F+N'092FYN-5\ MKT3K/(D1#7/@OZUE9Y_9%+^$3C&SVW=77*L.*+:RD>ZI)R6!XME]U6K#M@W$ M_1A/&7_F[C=G]$IRHZTN70ATU#MZ'G-*4PI,JV4A(0),>V!$F9-UG&U20E?+ M/C^_I3C8T7M@:WWX;&3Q5;8"D@UEP@)LM=XA]+Y`$QRF9Z?O^@)\-T$A2K9O MW`]]^")D53NH]@P"PKBRXNE66`X)!9HPF2$3UPTX`&N@)'8&)(0]]L^#+%R= MDR0.%[/9=+ZX!IJML.Y.(B<)^-XZK?YX5'SD\BS)D06>1Y;)/)Q=1Y,81/]# M0KU'?8"WS+'5TNA#`$T#DK9CV()Q!L0O1P2A(':-X)Q`4X.O%JKPL$JC)7V` MS/$C9.,AL`Z0>$!0T!R$0>QR802C,*86/=EXPU@F>5EF\AX9!.<$UL'YQ7R@ M]<(>,AU!I@/B)#Z`7!X?@J$"XWC.,NLQ%RA#,URNC.!>>4BMMTS["S$NV/P] MM`@^I?66=)2X])7.N'Z/$()/A;SEW'^3;2@@^5?*6421^0/G[JX2IQ"?1-#;@>H_#)X$;.5B'N;A.L)+_ MVJ?9NI^7=/@`\ZICE?C&3"5;&S2B!,HHQ/ED_,3S&Z<[\!+FC78PJ/K7&GY, M`FYE%`*XU-H];T"8#K^ZU5\```#__P,`4$L#!!0`!@`(````(0"/N+1AD`(` M`*X&```9````>&PO=V]R:W-H965T%R M-;\_J(KLP%BIZY0.HP$E4`N=R;I(Z:^?JYL[2JSC=<8K74-*G\'2^\7'#_.] M-AM;`CB"#+5-:>E#"8,L5E M30-#8J[AT'DN!3QJL550NT!BH.(.]=M2-O;$IL0U=(J;S;:Y$5HU2+&6E73/ M+2DE2B1/1:T-7U=8]V$XYN+$W2XNZ)441EN=NPCI6!!Z6?.,S1@R+>:9Q`J\ M[<1`GM+E,'FXHVPQ;_WY+6%O>^_$EGK_VPUGKCH4^9#^%F M=K%[U1[`=T,RR/FV59,^/8`4:BC11//%,0EDI*Q-8ZK?X$T+`5%;A::8_< M\<7MN>4V8-]9F^7E_(0`OTT\=MI1N])X\'H=U]\ M/.UX0^:`&?NOO?HRWIXMV8VD9>\]?Q\?)LFU\UGW` M<='P`KYQ4\C:D@IRI!Q$MUB*"0,G+)QN4#@.#>UP4+2O)?X7`"_0($)PKK4[ M+3`QZ_XTB[\```#__P,`4$L#!!0`!@`(````(0#K7,OG7P,``#H,```8```` M>&PO=V]R:W-H965T&ULE%9=;YLP%'V?M/^`>&_`Y*M$(56Z MJMND39JF?3P[8!*K@)'M-.V_W[TVH1#H`B])N3F.<],*BZ* MR"43WW58$8N$%_O(_?WK\>;6=92F14(S4;#(?67*O=M\_+`^"?FD#HQI!Q@* M%;D'K64%ZYE6,DA M'")->

1'S,6:$MB609U;!^=>"E.K/E\1"ZG,JG8WD3B[P$BAW/N'XUI*Z3 MQZNO^T)(NLO`]PN9T?C,;1XZ]#F/I5`BU1.@\^Q"NYY#+_2`:;-..#C`;7!ZF[79H#^;(%(L,%@"? M3LZQ-6!'Z(OY/O%$'R)WNIB0F;\`M+-C2C]R9'2=^*BTR/]:#*F8+$=0<<#W M&\=\Z4_)=1+/KL?8>Z":;M92G!SH&9!4)<4.)"L@[O<#1A"[17#D0D_#6A4< MPO,FG*Z]9]BWN(+<6PA\UA!2(SS0K(5!;+@P@E$8-Q97\EL2SW,F-;!9TULML%HG86JU,,\*MZDSO<; MR_% M,'VUFA1OI1"L7;'33;,ANKB4B.]?^+&3FAUE:&*H1-7S)E*Z8A5>=^Z;1@J7M MH*KTHR!8^!63-74,L9["H;),[B8X] MK_R5#TR;=2K!`::=:)$E=!O&=^&,^IMUFZ#?4AQ,[YF80AT^:YE^E;6`;,,Z MX0KLE'I"Z&.*(1CLCT8_M"OP79-49&Q?VA_J\$7(O+"PW-?@"(W%Z>N],!PR M"C1>=(U,7)4P`;B22N+6@(RPE_9^D*DM$AI%E.R$L0\2J2CA>V-5]<=]#(\4 M;C`@V\%P/PZ>+;SK93`+0>L=$M]-I/5USRS;K+4Z$-@L(&D:AELOC('XO!%P M@-@M@A,*FQGF:B#[SYLP6*[]9\@8/V+N'`:N_S`=P@?13AG4IBLC&)4QI3B5 M.Q?HRT3G96:7R"`XH7#M)G^SZ&B=L(/,>Y!YAQCX`\AT?PB&)>C[&:?6@29( MPW:8+HW@5KK+K8O,VY/07['%);0('M*ZR*J7N3"X.9^[Y25*"!XJN*KG(V$`(%:O/B_5G-EMZL&+OG%P<.-1HN2`$ M7[K='H;!>3^X,_O"[Z@A^HV:"YVQ]*8.H*5YL)I@Z5@"7)%LBT)X#`TMA?^Q M=%%E@*XRLG0J!=@QVG/B^H:KKY70N?@DRM(0KO;8$R*HF%VTZU?;",_9V_@\ MWKH^YG=?H(\T+!??F,YE;4@I,N`,O"6LO7:=R+U8U4#JH2$H"YVD?2S@CT%` MU0PPJYE2]O2",^_^039_`0``__\#`%!+`P04``8`"````"$`A1TDU2P$``"- M$0``&0```'AL+W=O[76U[I5:JJGX\>\%)K`6,L+/9_?>=L8$%FP1X2<+D<,8S9XZ) ML_O^D:7>.RLE%_G>)[.Y[[$\%@G/3WO_G[]?OCWXGE0T3V@J6;/#.F/&#(Y=X_*U5L@T#&9Y91.1,%R^&;HR@SJN"R/`6R*!E-]$U9 M&H3S^2K(*,]]P[`MQW"(XY''[%G$EXSERI"4+*4*UB_/O)`U6Q:/HQ?77DB>_\YQ! MMT$G5.!5B#>$_D@P!#<'SMTO6H$_2R]A1WI)U5_B^AOCI[,"N9=0$1:V33Z? MF8RAHT`S"Y?(%(L4%@"O7L9Q-*`C]$._7WFBSGL_"F=K,M]$:V!Y95*]<*3T MO?@BE+JP=!`2EE0 M'$&R!>+^@J`2Q#XB>._#4,-:):CP?B`DW`7OT+FXPCP9#+Q^81I$`$F;S)!M M?&8$8V9L+2[ER03::;X6TDD334F#8-"FM?B'5;-ZD]A`%BW(HD%T$@-D?'T( M!@G:];BM-:`1J6$FAF\J4MO(IM6!PF) M^GL([.,+07`WDXFXA>"VW!IZ7<@2JKX__7A7E[^*P"Q^#3NY,0Y0;SOG_50( M[J8R$;<4`GO9>%Z-[A+7H="1&Z=Q`C6B+>HJU$-MF5\KL(!2[K>%5*XW^Z+> M!^I05X-E_SB129N!1EL5U>['AT7;&F22VS7:8JYV@)Y>37(S/I5L&6[YF?08 MFCP,J^!:6C-!05T5OK;.;J\FN9JXMJY"/6:PC#TP3:ZA2>-H1^!)_B6N@:N0 MN^C0R&[0 M,O=`':ZG-8&NP_8"/O0G".P:6!/L_9[1L0RLO;`<]H+KY+!QB&:9&"-MJAO&3BR#*Q5B`:]H&^S4C1.;JD0 MSOM5B":96Z.M;+?,'5GF'E#!];0F@&0]*DPR,#;1,G`5ZAD=R\`CGPMP#'92 M5*'.CA022P5S^#6'PXR5)_8+2U/IQ>*"!]L0CGM-M#ET/^J&V/'%]M$?22]D1..7;`@%7`R'::]N]WQDXH-&F3OB1A=/RYU4#[KD MW'C`T.C$+XUI8T)T6O*:Z4"VO(%_6,(5,[!_78I6']CJ]!*ZFJF';7N5RKH%BHVHA'FV MI+Y7I_%]T4C%-A7X?J)CEAZX[<,1?2U2);7,30!TQ&WTV/."+`@PK9:9``>8 M=D_Q//'7-+ZA(Y^LEC9!?P7?Z=YO3Y=R]U6)[+MH.&0;S@E/8"/E`T+O,PS! M8G*T^LZ>P$_E93QGV\K\DKMO7!2E@>.>@",T%F?/MURGD%&@":(),J6R@@W` MIU<++`W("'NRWSN1F3+Q1U$PH^%B-`.6#=?F3B"E[Z5;;63]SX'HGLJ11'L2 M^#Z03(/)+!Q1T#Q#0MR&K+];9MAJJ>3.@Z(!2=TR+$$:`_%I0^`$L6L$)SX4 M->Q5PRD\KFA(E^01,I?N,3<.`Y\OF`Y!0+13!K7+E1&,RIA:W,J-"_1EHM,R MHX_((!C.IK?Y^;2C=<(.,NY!QAUBX`\@E_M#,!Q!W\]Q:AWH`FDHA\NE$6RE MN]RZR-C>B/Z)38>T>`FBV;F:P45#>A=9]#)(PS<.#]@O-X+@H9*+'!O!MMPK M>GN;Q_,`?+]?_[ANJ+"/0$-Y*?=P=+H@P'%?]7TI!`^E7.38#`7Q/J]U,P?T M^P)VV5#A$!JZ>:.\L5;[LF?4$/U*S85.&/I09Z#[3N!ZI>T-AU#_IM!PTW(.1 M+6P49H8T,&SLSQ)>+C@TUA!O02ZE.3R`,NE>5U;_`0``__\#`%!+`P04``8` M"````"$`ZRWWU34!``!``@``$0`(`61O8U!R;W!S+V-O&UL(*($`2B@ M``$````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````````````````````````````````````E)%!3\,@&(;O)OZ' MAGM+6$;QNQ4`)HMW\O[;HZHQ>/Y'UY>+Z/2UXV!"AW`HSF[O"B%I:)Q\.@:"RXH M\$DD&4^%K=`N!$LQ]F('FOLL-DP,-XW3/,2CVV++Q3O?`I[D^11K"%SRP'$' M3.U(1`-2BA%I/US=`Z3`4(,&$SPF&<'?W0!.^S\O],E94ZMPL'&F0?><+<4Q M'-M[K\9BV[996_0:T9_@E^7#4S]JJDRW*P&(=?NIN0_+N,J-`GE[8/LW5R?> M[TK\.RNEZ.VH<,`#R"2^1X]VIV1=W-VO%HA-`8P M00(``,@%```0``@!9&]C4')O<',O87!P+GAM;""B!`$HH``!```````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````````````````````````````)Q4RV[;,!"\%^@_"+K'DOP("H-6X#IV M4Z!MC,I)CP1#K2S"-*F2E!#WZ[NRX%AJK!3(C=S=&2^]"HP56LW\ M:!#Z'BBN4Z&V,_]AL[KZY'O6,94RJ17,_`-8_R;^^(&LC2[`.`'60PIE9W[N M7#$-`LMSV#,[0+="3Z;-GCF\FFV@LTQPN-6\W(-RP3`,KP-X=J!22*^*%T*_ M89Q6[KVDJ>:U/ONX.10H.";SHI"",X=9QM\%-]KJS'G+9PZ2!&TG074)\-(( M=XA#$K2O).%,P@*)XXQ)"R0X&\@=L+IH:R:,C4GEIA5PIXUGQ1\LV]#WGIB% M6L[,KY@13#F458.N?_P=R$+9G.ZN@CYH1W0 MB)Z5K81"98))BAS]D"']HK';-9"#4?V!(YJ(K1(X]]AQ.N=X`(RL218Y4UM(3S&O'?7.>FP6S=`)D!```&#```$P`` M````````````````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`( M````(0"U53`C]0```$P"```+`````````````````-(#``!?&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A``^[G923 M`@``K@8``!D`````````````````NA$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`)$'!O!I"0``>4D```T````````````` M````]QT``'AL+W-T>6QE&PO&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A``A\X#?R`P`` MXPT``!@`````````````````RT$``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`"I&,PW)`@``X`<``!@`````````````````44\``'AL+W=O&PO=V]R M:W-H965T^H"``#("```&`````````````````"(6P`` M>&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`(4=)-4L M!```C1$``!D`````````````````J%X``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`.LM]]4U`0``0`(``!$`````````````````1F8``&1O8U!R;W!S+V-O&UL4$L!`BT`%``&``@````A``UX!C!!`@``R`4``!`````````````````` JLF@``&1O8U!R;W!S+V%P<"YX;6Q02P4&`````!@`&`!:!@``*6P````` ` end ZIP 13 0001551163-14-000244-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001551163-14-000244-xbrl.zip M4$L#!!0````(`.QC$T7V&%#VUAH``%B6```1`!P`<')T="TR,#$T,#8S,"YX M;6Q55`D``]Q[\U/<>_-3=7@+``$$)0X```0Y`0``W#UK<^,VDI_OJNX_8.N2 M>%(EV7H_[$RV%%EVG#BR8GN2S5U=74$D)"%#`3R"E.W]]=<-\"V*DBQY9K)? M9O0`NAN-?G>+_N[OSTN'K)BGN!3O3^JGM1/"A"5M+N;O3[B2U5ZOW:_63_[^ M_7_\^W=_JU;)Q)-V8#&;3%_(Z/)Z<*\"[C.BY,Q_HAZKD(&]H@(7#.72#7SF MD1LAY(KZ@$%5X(UU6H'OW!>/SQ<^>3?\EC1JM5ZU4:NWR']/)O\8_'+U^_"_ M?OJMU9K<3QH_W5__SREY>GHZ9?:<>AK;J267I%I%DIZGGD/@#$*]/UGXOGM^ M=H9K\>-3ZF[T_0=Y6(]Z>/BO[A)QI.'`MYY?2"I9,^(^PG5A2^.S9O\== ME["^7JO_;W@EW]=KU5^_.\MO68,S81Z7]DC8E]0O!X@456N=:K.6!9N!$,,? MP%3' MP?TO@^'HP^/-<'`+JNRY!D\1Q!RZ(5#A4>=&V.SY9_92BJ\&PM+J-]N-3AI\ M#D(,?QAX'AZ1*XLZ?S#J[<+\:K7>`%4T\#=!R!]!+I=2//C2^OBP`(NG[@(? MQ1)-)K&9Q9?`^?M5KO;K-4;F4.6X,B1 M,PFF#K>N'$G]?;!_>+@L1IV"E\-TQ1WF#8$A<^F5W]P#$`%KR3USI>QN8IX_X-/_4"5XAS+#`,+`>2P_":=0/C4,Z3L`SZW,P?W=^8X M/POY)!X855(P^T:I`-BQ._P-$-;,3"*K5_!)^0G0T&1-3&[W!NC&$&V'_VNC M"'IJMX8?>MCS(56+O>6UW0=534/8$V0S#[#3*P,X4(KY*A2EPXC-@'HMDG+R MMZ$XQ@'V!KL+R5F@EB5!M=2$OM"IPP;"AD^\@-FWG$ZYPWW.7GTCG7J_W4IA MWQW5VY"XSAQ0J.,3>,\@RQ(ZESXY% M:<&=-UNM-*W[87LS0M=9VNJW:DA7&<*&)5ZH[]U:K]:.\IP<0?5F M&VQ%RE*4XLE0-/'DC"FEKS<#R@9QC607D2M?6]Q8? M0)D2GR*0!^(L$*,WQEDN3LW:&R,O$ZNW1EXJ7>U>O]MM[H/_F@GF40=S3GO) MA:[H^GS%=C"8A<+62BGR%MC'HZ-``%N=3TY'N5#V^I^!H#)![=<^/4&EPMMJ M=1NU5W+ISF7XI9B'7^[O9(%1W93LK@$\!%V1@:PWTL'O$=&5BV&]T:BWW@AO MJ;=MM6IO=-Y2H>HWX--6=U?,-\*22W8KE;KRY'((:+@(8'&X2XK]!:N:DZSM M*(Y*48'L57/"]TDI*A?/:DX^/S%I91)BT:MG8)P&:K35P91F"F!W3,UAB;?EN-K#_#)2O^^URXG'IF<;2->4"3W,G M8+.[]3,R_)`/V,63_B@PH-Y>] M=B=K+C\S"U*6,C+9!J:N1=_-"C>/&>P\C`^M9JO6;M=WY,-!5*Z54[B/0`XV MVPFH5V'8P4`>A&$_4W0@JGV4_C!4Y6)5;_1KG5Z_MQ7;B'H"@A(%"J7'GWZ@ MBEM84.5.X#-[+^%0=@0%**B=I@.1+6B.1U+S2R-IL_A]";1MDM=/1-NSXN<" MAW)]+V"["GB*MG"L-$+W.\,Y9V8/5F#ZYFP<+*?,NYN9N3X]UV5K"O:1ZO79 MP7VQO0&)S2^=Q(U2_T72ND$+/A>MK]&*D-:<0H#K3Z*%XSG)#-C7(MS'51X# MX;X.X(\8\PV_$2/F`%!3^*O`#CZ5: MU`CF$*(:[6R99V_RXW@&][U:_OYF9FS&^":%EXM_J=4IN_=,26E[R[_?; MO8,IA93%8LS6::Z1E1OA4S'G.*&[=2)ZB\'/ETJW(]NB[KG9W`/Z0[UVJ6[G M$!V3K'*?W&[4/P]=Y37O>K_=?BU=QY[?7J]E=/OI6LEA`]Q'IK:H!=MIM[J= M8]$[\9A+N1VV^5X[(]WJUSN=S$14`=3MTI:;YC^@2=[K]!J=+1*7PY:/6?$' M,&!Q5MR&H/_E@V(0L,5MT8'E\]5V(LM#]O1LP>X(WX3.4JN2'LKXO'26^XMV MK5OK-`ZF->UFM/_;/INY7\MO`X)=&'8C5DP=BV%YNG;'N9%?V$/U^!0K1SO, MFF\;)JVEYY/*T6RD*&4/7R[9M-2V;:%GTQWF4>0F;5WZ@E&]NIL=CQ;(OMNM M?BK?+$.SBV!=<4&%=2Q-K#<;F<[1[DC7?L/XBF1]=ZN[&<%1Z-C9JKXM'>79 M7_Y7I#O2`2$%_H>F:P6Q.`C>`.[8\U[@.E_SHYJU'Y]N17!LD@HFRFN?F:2B M8+7[N?FTRT^1]R-*.T$,4''+H0.2W7;!@$T6>*X.)6S\T`ZM$77PY_%,V])' M0/F#(ZV/I;_U_L;Q+_Y6K;+Y<[7ZS=R_P/>NQXCR7QSV_AOJ2G6!FZO4X7-Q MCGUR/GLQGT?KI_AB?/5H_#"Z)%#.X)0^/@\?1+Z/Q MXP.N/YM&.\\`U6NP/BX8H9`[Z$<1X%,)9M'Y`43$`+*@*T:FC`GB8DSOF4?= M`$NCAQB0)^XO9.`3&MC>%".F!"!"/8>:")*8V?$L$LYA26/KR)5*G M,'.94>XYAL#D/%'WO0*@5.``-B!&QD->0(RP"'W,Z0>3[E`O@Q0R;H@7=#A/2% M]$$_N+(Q`%Y+P`V0+.8)_*WV)S26#3"6UW&Q0096FB/,`J`H:6`W^YP]'P`W\L"<3`;I72"$OWOLN9*A2F\J M1B1B+!Y?5HC"EF'X2\X\4LTF`&8L*]*P9$QC0"[@ST'P-A.\+)SF+S8&.ZAV MMLF:W.T@EOB)=/!&/DOHU"2AMK;!`C_<7(]OKFZ&@_$C&0R'=Q_&CV@G)G>W M-\.;T88@BF@"MJ"_<$`EJ@L]*W!N-"9+48`O/A@%BMI\AN=!@O`XZ-!2&>L3 MJW6AE3)^$F,)+&5IV2RP1\6&RV,@%QAG)/&;%C7ZD:&"FN-I'0-5#I:N\7/: ME]/9C%E^:);PZ5.(1$]*JC7;E!@C?)_$-[C0:.L<,6_:8[#8^)"S4$LVQ@"; MR(GM"BYB\:]J=/\^M4FS1WOOM,7`$"J%,-. M2\5@2;TY%]6I]'VY/*]QD?OD%)\'Y_KEHIA8ER-*7"S@9A+F'3:*OT5^$/,< M#*)G'-Y&V@U*!^=($*$VC6B6+>I8YID'F)W8?,7MZ,H*W+A@OH&1=:^6(3]C M;\-#C&0FNS*R$DH(B0;I6#AH=RCEW/P`A:XH=W8@W0[1 MEQPAI%VFG]R7G`/#QU,=S[X.5.@UI_KJXJUK6TQJQ\(T"WR;*]'-&VLFL("IBOFFBS@HPF3(1K0X9!A!8XLZ&5A_2%#$]7JGHFY211T_^7U\AZ2 M!;"3B4O&I]0*>&T9$_AVCB@)2R"M`;X'6JX]0T_&MZ3IB4PRAWNWI?8>&H*) M(77JR,T[-,E6&.B8"#&)(CF@!D\CQ2;=62\'(.1T]I9P(S7'M5.,DZOX)^7W M1X\*175NJI*HZGBQ42A\^N'!Y]73-LCC[N%2*QTN9>,A_>)^=#MX'%U6)X/[ MQS_(X_U@_#`8/M[:K1K/2;_8K17IN5JPE]KHTA-(%5L9YR67RBL510D0&TI0( MM*X?P16#Y\>W*AIJ<\.&!QIC3`7TXRQ-9,25/HJQ;_))A(L2AIAG$AQ41,KK M)&BB])`<:IY*K4Q@DF8MST<_V,='RO*+0'VF;$&=63XGH2IW5^$UJE,RV&!V MM]Q&)8R]"H!FK/J4.KJ:Y4L?;#Z(0;-5:37[)+E,(QRM2K]5(ZGDRUQQ1&?H M3D15IV`0K\%!J:_*"R+Q2ZZDMB#JA$'E&XK=?057)@,,*I(/Q,A44Q0WY3,GH9*'G^- MSB41#UW*1'>&FN.#6%6`"5&-+5D&Q"=O]"GB&A^L$^9$I^NWD7_B/;#H. M0G^+O3ID=6KC%^=W"EQ-N^"S3#(_N!V1NRLR`8>T5P?DM80F-F/75^0X3O%. MD)^H"+"M$5I#^!<".!_SZ`G$RDMJ,0B&(7'0#QN78>+_#N4YBG>Z%[D`J'?Q MK0Z`'/Y/%&)T5R`2^)),J"YG30+/6F`G>3#WF,GQS-/_"HNA43M,ARWA5W`#?*6MIR$N M4J($ME0>,'DBDT] M;2C`2-2(F]*#6*L'2$N8[22*K<&/49IL\R=(THIJ/L_IIJN%`$5OP>``8_9$ M?F*>TG^S(%7*-E?_(5;;C"Z6DH1G&]@V^,A@F=55BFO"UF`8]F.9SE]7:)1R M\V=43`!MRC"18D6WHD-><\A8-V;<`PW6YL:G'TU$CP-_\4\R#Q4[M:[R6$"N>M64^20$@_SFR+F;^A([A'%9*,?:\'L`'\4<,_[R.]SZ[PNG#/TQV,$(O][=(]))XAAM"YXA(XM[G8*8 M:56MLSF#][.T.?T8945@@67@5LCM[;"2A.TT>7D)3@O_AI-QG"SI-B0V3RM) M@B7,]M7:>(S._K+*OY?B0NL MV0`EGU/L<05)<',(%)6MNP:N]D(0$F2!(=EQ9'<]J8S;C#DO&/A]%0YXCS,/?3E(65OE18 M^8#9O.D?#2R-IMYO-I%VLS5I[>4SC\89MICZRQ-C;O MJT8[E1V$@**QMOC6N3*U8(<5@`KMDPYK,02$*"UF>ARX@3NAN*>"%2FS+QI: M8SI/Q#2/<0S6SLD[KO^JX->Q'0W[=C;%@;*5=((E(^\^G#Z<@F'S/C)?CU]^ M&RW/F+\H;?(7(,^Z8J_[A?0%J]U<>I'M2VBND"76Q2%=3(9'(PI"#`:8(0>C M/%W-A<@4(&(YCB\A6^8F_W"QG13W2%.\P&!MC[@D02PA!P:@)RK]2QL0/A$#J+?57(OBAA\=A*5T+-2]6(GVDWXB%RI%/6`:)KT\7SJ,[+!2E5)-YAM79C#`E)TKAYRJRC\PV M1PEI7@:Z3&_R&=-!ML,F.U98=`?/9ZG=.E0PZ61N"$N;2"0Z&?.HI.Q5O#B< M5X:4'M-10W29PY$OB=2)+NW<>G/HW& MP$W.+@,ONK(9U;*$$WE:`A(PE9ASD;SA@".$_WK^506`6Y?20UD.E^'@#9@Q M/JMDIC`R%QF*.IA,V%8IB.VP`0FR-Y4KEJ?J+WAE4>E$8F\K'5&(*#:%\12IY8KAU'FTOH+?9Q>` MR?#B[R^TD?G_]JZE-VT@")_Y%[ZE!QP#A@0B-U*;<$"5(I6$2CWR%[/AC#.6+J3SQ'(;Z[-2$)0D%*G MEN41UF.!O8/4$Q"Y/EB\;F9I+&(_(W\JG\JU8HMPXAWB<1VD9G!.0%I[AA6,=9CO8`FY1Y47\$HJR_LGFB?"2+9)J`AB3JD)GP8TF!@!(P/7L[G."4_]9Q2-Z+TV]31YP!A!-(!J\O?;7%>(MA+!/M6!/L6%21U%6IH!9-U-83?*QX7 MR]#GBA=,\.MC@$X/B$_]KV?/\_G+E>.L5JOSV!^?/X5+YZ;WX^P:Q=OLN"T\ M_U$U8YJ.1M1CUL0#8$9&\UN0QS7*R:[5X<]SU%6^"P9`N^?"QI>()M?X`8JH MYP@6U]CE(Y2*X#*8H?.:&_U/KNW2?[?HWKMVO6&[]7UZ_[NPT4_K6/,#=8Q? M0%$XE^X;N'3WYS)UQ-YG8'>KX3B$7?/@LV+9K7?:EW:M;==:'V)Y32 MK3Q']5)RY3FOHPA/IOT'4$L#!!0````(`.QC$T5O#Q\LA@4```$]```5`!P` M<')T="TR,#$T,#8S,%]C86PN>&UL550)``/<>_-3W'OS4W5X"P`!!"4.```$ M.0$``-U;6V_:2!1^3J7^!V_ZP*X48PA)-XF:K2BYB"HM"-1NM:M5-=@'&-6> M<6?&$/[]SAA(C/$X=I)B.R\0SYSK]QWFZKQ[?^NYQ@P8QY2E8S!&# M`Z/MS!!1`AWJ^8$`9G0)H3,DI`=^(!_L^H'L\Q<,3Z;"^+WSAW'8:)R8AXWF MD?%OO_^M_>GJ[\X_'[\>'?4'_<./@^O_ZL9\/J^#,T$L]%:WJ6>8I@K)Q>3' MF?H8(0Z&3(;P\_VI$/Z992FEVQ%SZY1-+.FC9:T%]U^_VML+A<]N.=Y0F+?6 MXDWKVZ>;H3T%#YF8<*&R6BIR?,;#]AMJAWEE<&EH)=23N18S59/9/#1;S?HM M=R*!CK%[Y\9G0E@*L,;;5B,BHZSD3']+905`\_3TU`I[H]+2G"/NQ*/6CZUE M9TP:IX1S!ZHDD_$8^;_B! M6P%2WUE[4D$^,G[E<.71I7;42\U5%4=9+9I.+4K'&/%1"''`S0E"OO+:LL`5 M?-VB$F^9C>:JQ-ZLFK^W.9?.UY9=-`+WO!;KM(H)K8/X5!-8V!4-*\)1FVU& MB)B]MB+_#`FJ::MS)6'QP/-":Z8<>;RU_IA1;PN=M3,:"\\(N/1$?64%N36# M,@?8:K2=@QH&EP\%H;N,OA,P!D2D\K^6*2_>L5R2@3],`[ZX?&(,5*V,;C`: M81<+#`_44H)@495OVS0@@O?1`HU<:!-'MK``G,RYY+%0=)7ID]KX!>7!I-P5 M&4ME`!)P_)66(HT`0NB0#F,\SA`L;8QD(N*@(O"&>8BX!A,HEK M:-A\!L/5(/XY$$RND:-HC9CEV`K*=47FV?I!M:()SIK7+O=3%<7A%VTVJH+& M#M;C58$B^^_@J"1S8"3BAT>RJG.B(^/X)=1>CAW+VY>0;]8-P9\O(=F<*^R3 MEY#SKUMM<5W,E#V054X"[7Q]U[TSCM6-WI5+Y\]+\;W573-\[[F@HW\0 M*H0^HS,L\_FP^"(#[))5X9%)VQ9XEK9DRV&@J-L-$%UB4P]N*$_)(B)3]`B= MGY2-/=)FOF4_2.:B-QX"FV%;6V,QH6K3$\\XPVZ]R#,I64H,D%H'+;^[Y)(+ M[*F%T%4@`@:1A9!*3<=A?CO5IOD1N&4XK"BR$JX1)CVF!I4>&2(79!&K56&7 M#(,1QPY&3'=`F46SVFQGPJ; M<0BTT]MU:@,X7(6_+-LN$8A,L#IQ3WNO-8-BM3G.@DR&`Z]RS=RQNX3,,W5< MK]K49L`EP^E>Z9B-W8WE(3>N^@+YW4(GPV%FD11K(.B2&?"G[,N3#)1@\@GG MSM1+;IUT26LUA2C=-+.!0;EW[9JDKS!!Q'Y"=289*$%U=B@1#(\"N;!+?[7J M`:62UFH*;;I:34*DW"4;C3ZR2%]WZPZU(?Z/UC9\C]02P,$%`````@`[&,315#$M.6)`P`` MJQD``!4`'`!P_-3=7@+ M``$$)0X```0Y`0``S5EK;]HP%/W<2OL/7O>AF]00'NW4HG83HP]UZM8(UJW: M-$W&N2'6')O93H%_/SLT#$HICX2L7R"QK\\Y/M>Y=N#X_2!BZ`ZDHH*?[%9* MY5T$G`B?\N[)+E7".3P\.'(JN^_?O=@^?NDXR)/"CPGXJ#-$9Z<7C9:*J0:D M1*#[6,(>:OAWF-N`IHAZL0:)+CD7=U@;!K5G;DAIS_3UAI)V0XU>-]^@:KE\ MZ%3+E7WTP_-N&Y_.OS6_?_RZO^^UO.K'UL7/$NKW^R7PNU@F;"4B(N0X5A*C M_'?=?G2P`F0FP]7)3JAUK^ZZ=M"@(UE)R*YK.&IN&KCS8GMK*PFN#Q2=&M"O MI>$5]_;359N$$&&'2U"BN1'VSDG#'-OD5*I.K5(: M*']":$#9F*8GM7:M8>6WM?)$C$595-ZW*6CW+M^C1R[V-T`KJ5T28YFGP#'0.:A,@)X*H`S)/J5.X$SI3D0\53I4/-]%& M??GK5)#83%JGWPWNGW%-]?"2!T)&2:5;+-N".REXHF]I[`GI9HU03FWKE;F= M(H6!!NZ#G]):_;E,;7WGFL((X@K\#YC9BM8.`;1:UZLY:)MS9S'ANGZT-=9@ M#5?7P;6I6*-30&9CYL`6X-!BYCRL:F(5GC/1S]>I?Z@%&_4H\:K%B2K"A(HE M?!8:*F.><\K-DJ68_2-BDQV5B^$.?`;*@)R_1+_!&11=LUE MS61/K4V[G`:48+-S$")BLW7PKB<8)11R6FX+.(HR<'D9F1S=;P$SJ]CWL-3# M+Q)SA4FFK6%9^*)\7$I!)@L/VIC!=>`9EMQJW@/,HLR:3YO)H;=M+W>6WPF9ABS/L">8-;@\WRBSM M,Z6I>2F,8?Y>6PEB\5M,"79'0*+C)K2RIY'LE;7>QFSG3F.*XE[<2FKXE[5&.6;\K6 M(?[OY\`%VHZ3'^O'_VR8EK]02P,$%`````@`[&,31:JWW%JM$P``,^<``!4` M'`!P_-3=7@+``$$)0X` M``0Y`0``W5W_D^*XL?_Y4I7_06_SZLU=U3`P.[OW;C>W27G`S))C@`)F]Y)7 MKZZ,+0;GC$QD>W8FJ?SOD6P#!ENR;`FCO1]V!XS4W6I]K"^M[M:/?WY>>^`) MXL#UT8>+ZZO.!8#(]AT7/7ZX<`._]<,/;]^UKB_^_*??_^['_VJUP`3[3F1# M!RQ>@-F[,Z9!Y(80!/XR_&)A>`D,Y\E"M$#77V^B$&(P0,A_LD+"(;@D7^RK M2_+;Y@6[CZL0?-O]#KSN='YHO>Y M_?\5^/+ERQ5T'BT<<[NR_35HM:A(GHM^?4__6U@!!*0Q*/CP:A6&F_?M-JWT MO,#>E8\?VX3'37M;\-7O?_?--W'A]\^!>U#AR\VV^'7[Y_OAS%[!M=5R41#2 M5B45`_=]$#\?^G;<+@&6@%F"?FMMB[7HH];UZ];-]=5SX&0$7;K>CLT&AV&; M*JSS_4TG4X92J=C\7)54`=?OWKUKQ[]F2Q-R3K@KGJ7^MIW\>%3:Y8BS4RKI MR&]^Q+X'IW`)8I[OPY<-_/`J<-<;#[Y*GZTP7!:3\S!NT_IM!!^M$#I4B^^H M%J^_IUK\0_IX:"V@]PK0D@_3`5.R=P>TDDKMIF2<0.SZCHGJ"7M4NV&I9Z&% M0PFY,_4;DWQ.QCY82^9,S>:D]4/+JR?MOF8B;3)RT@=#\NE`:/@<0N1`9RLV MI<-YCV,V\4A!"6\I^W:6YH5'ATH?7V0U<9$=1Y96L(AI1D'KT;(V='R[:4,O M#+9/Z!1QT^I8=IVMM7-+F+<>XJ1\N M!"NULTVA-0\:@V'@1]B&1[3)GU^J"15K]J)$LY3X!9W;"!\Z+4/4>IA=_"DE M!>P]=3HI^\NE:T/\8WLOV7%;#&P#'SL0IS-^MFD6MK"J:YP,N%->P-HS`T[,#80K")P]2Q!0GKK! M79T6CU\)U1AI[K49NM;"]=S0A4$WPIB(PW@-"@I*PYK-7`:F\:P*4H(@PT,W M/+*;?XRO,N4WAY>N%:R2A2'9-&)H480G?QFXX520QD^Y,#(X&IES,!AUIZ8Q M,\&W/3/Y]!UY!KK&[*-N:"I7QC&J1+NF.70=RS%`9A"Z:SIL]J,PPC`S;';] M(`P8H*M.1QJ+M4676F[ZZ[6/R&SKV[\"-P@B,B,O?0R(O)!`9P4LY!S,RS;E MK!MR:ZON&-"2W5X5YP&TKQ[]I[8#W03BY,,QLLFC7\AJP`U?TH%["C<^#LD* M@$S[870,X-+BM7$J*H@,''GT=0&=J!ZVV*K6(PUNL'W/M5_F\#F\)5Q^-19! MB"V;M7ICE9;?4O/%D$%33%K#95M)DW/;91'5-X>;6;39>)".@)9'%P!]S_\R M0&326,=6\Q(1>L%Q./E;&41X`SB5H-1G>ZX;6JHHX!6Z]+FT/L-%UO&\C)+#'-YPU$S(TQOXXT-H5$D@'DE+'' MT`U[0HHX!ER%SFD.9>,-03]=>:9R!"63-;N\-+I*19':1OP\,4QA.B4+>V#,9N9<.Z1PFWT,%P'5-XT9(;"H1HE*>.@, M"S$\G!L(=Y:+QGCH!\$8S2P/DD4Y-48/T"Q:!*[C6OB%@0Z1FM*0J2">#(XH M`T`[$3ANL/$#EVZC@;\$P8Z-;B"KH)ECY%7NN0;A"!%9Y].4( MW2?(WXJ5U9*'H9A8,A!,6<2[,>N`B7;($U-&#G55.JE)1S>XA&1.=N)WX)/E M12R4%954X-+&9"]E>]^23=3OP/!+'5!5A1N/*Q^T_H7%HA^._. M5:=S#386!D]4B$N`_&W)]Q\"/0NI>3#W9=4,E1Y%Y![B2CFS0FF^OH!/1 M(3AUOWM`;ACL#AM85OR26O+6>S&QY(Z^]QZ6*1/=("6HA9QUODKO-.DI]H^( M3.[A2\\-;,\/(@SO?/(B=ZDB,!KY(6O@$ZFIP)=,6#PIIR!"![P&+1`3!REU MW9!701EY5[.*G=4<`DV(:(OK?EN=CKRYI:[H4A:9E"E92<9OB4WFO]7P[HH=??3(?6-Y?H87[Y$F1XQJKI)3/6@E[J7B&8M*Z M`$R@]5DG-2'MGPHD*3SWO$WD]*S[L%@&3HK+*1E+"EFK&$D.".L$#V[+BT81CM;/8=V8P@WIUY450.,10Y@X M<$=QE%4R/WYVP]7GE;\N*!B8SS1>\;I#VF23[ZFY>N5[1/^!2;8[X8NXQ:0Y M211:81I7G_06^WNR\(OY@$DJ$-A)I,N+I8&>V;:C,^&TV4@TZKA*U\/DXW[/ MAYR^BRQD'^S_]M:,DD-K:;)*HMI4-$SJ'1R/6HDK]&!DC+J#T1TPNO/!I\%\ M8,ZTXEI6>/+HK(L_1'']6$=U7BIX)\S49*67J=OT=!&`]G M(/3)J$UAZ7H0>-29BCQ!,`1TV@5+,@6G[E7^5DY@?6W'&C55+/@^20&IP2P] M9(V4B`6=G53&FFY,QLL](N;^!+L^3HP0U-TL<3;KQ?R.:4*I)P8Q[,9N#7[XZD)>H-9=SPBD]2#V0/CB3F-XR"UFZ9. MJLM7(.R.H"A))6Y[/B<+3=Y-;]2^H]0W8[9&N$R$<[.OTEA]-V/UMZD?]'=AQ_?HB\8YL;_=,PJ%1=K=" M6E5BW)"E>H+M:ZUF2;DWKL@W&J:'LN;UF&\<3>KIFT%9D?;*=\(2J&ATD$^, M1M3BR![',V54#-5YEK*C,3T`T@UIA0TM&$59RFUTH$Q,RS"86*[#'O@.2JD8 MR(K82AV4QR1!3%,W/#":6S"2L-5\%FM_N95?J75?G>$L,<`F5'5#0T&#.3;] M\Z4JV%_#"9TAC@$*BH]&X>OG!263(LNLI!("`'S(UFKI@*9!4RELN/L:<)*%$-$538Z`*\ M<-3=H-$KYV#.LG;E"\J;N9C,Y:>M+.W_L39^\$>0W@FD&V386LB9MTKZX)S7 M%Y5L^#D53G"=T2E2&0X'QNU@J*77:+D"RB\V4K.)KG:N^!EZWD_(_X)F9+?O M(^C$*:7Q45>7EU=PUE@BBORI(X.!+E`2UD3^)%*H5QK>S! MBMG+I5TJOG%H@^&&;'!!`/&3:^NW'N*HHW"GQNL.'8]MZKF?\P@U>(RC^*2V>8^)-1G+#QWB?-I*Y)N-64G%KFH!0\JLS'A== M(%5-)P7WJ`GWU*E3D,P)V0)`'?RL).%(EI&*/".4GDYP*&IG45:1O$;/8_V. MEWA<,Q.KM%([=X$8DD;)F'02*G=HXM8%+8)JX)FUF=W18.X)/Z!),=*]#@-" M1X7D\T(4,I4!S)86L#/)=!U@:/W)B&RF^5X2<%SQ13` MI)BQJET_S04ND@S\;389^)LWEV__]^:R<_TZ=BG*?#W,$4Y_S"0)OZ0W&6\@ MW<1`3QL?^3)-YP')Z^-SGK&4W?;)KG"",Q>E=WK.Q]V?/HZ'/7,ZVYZZF/U! M=S#7#43E>B@_?3GWWCYCQ3>04QEFPM55GM`("2H53KT_IP'&J`>^'DA6U1+G M4*="?S8X#KJ/R"4K'`N%F8"0]+;ITF@+LY4%TD*;W M<%?34&X4K=&/9PZ[SF:'9J"SO-YI`JZ+1)-*#G.4!EPW[`DK02C(FMU!S;IG MN2''+^2R+O M*U!0?2V!B+@J1Z+D@C7-TT#4T%');03B?=H<BNK9!IA3LJ)`V_ M8J8R"",4J9UV1U,W,!6W^!@O/#V?W6&B(#M:-4>)(@(-YN)3LLPOBG/=\?KZ MHELY:JJ?,^]L<[#CQ'?&6AX-$QJ@].8WUGS+*"T_M_+%D)I'=Z0!=11KN0C8 M>E[;5Z*$W$0ITAG-(QS5#.@)5Q=&FM5!94! MWZT5N#;XE@:6?@<(0Y`>:,2,=<-?5<4<`[)>%Y[/MM&+X.Y8]_#2*T$C!X>` M(FF$(47MQD+:G8-5UU&9542T1QMT7]RN M%;9=Q,!FOIR\XR*+M7QPDJGI_I79Y)RK(E_=^AR!U3SZ.OV1EQ(PC>?&$/QV M#[SJ'G2=-ULF:_.@*&!;75!V`A]C-C/GVAEP^='6*B*J19U6C35$3GS!HV<5 MN4$?_B[EMEK(2FKSER6H2Q^Z7Q_TXF[)CPZOAI(K$4K$D75PT&Z)*]#FH@L(A/J@V4OX",#I'[KD>;(\ MFD[%"+L6QB]D6#T8A&(([[8&).!^,> M#WQG;\\FOJEB%I(-]O`WV303.64-,\E^1:A)9_$SKJ*6HCL,*[YES0X?G-%! MS@U=!0_NK*FCW:<'1$G#+$Z468.H,F\V((IZXI\B'XBN>4`DU%08AR'3S0UBF\SZ0RK`PK)_S;Q_XD-R%0KR6*XN MKO20_)8ZP*RZ7*/Y_;2^SQ0?8]/=>C4;F7![*,Q->F^MCN^OQ^/DA,YW3`GJ*(R+Q=NUVERP6TF!S1U M^*JZ"PI&5NS&!64Q!DK%BQO)IQ0[IZ@0.7KOSJ<-X&C]/)JFL8:L' M%^R-"J>*TIQ2+('4)9;""0>0&"XU#=`540DOR12_DYHTIC]!,H&RG+EV/RLP M@Q\RDL'+U/QDDK74#/SK^M\JSP?KR!A"'$#6\=]64-W0>]S0O#F]J-O/XNW* M`*;2.]X57^6>@UF;EV',&. M)=CSU`5TM?233]E9N0]U3')1[U80'J$&DUZH=`%/C?I?XZT@`IJIG^_BW/[C MA\<'W>2X@$BX.R_@Q("7551TI;&(<&J.H?0]>1+71/$%R.+]=-JUWR??BU!H MX9>^ZT%<=`I47$[!VH_!6G[M=T18%^B4MCR_]BO4>K8]0_*)/-L^(O\MK`"2 M)_\!4$L#!!0````(`.QC$T60?BNLV@P``&"]```5`!P`<')T="TR,#$T,#8S M,%]P&UL550)``/<>_-3W'OS4W5X"P`!!"4.```$.0$``.U=67/;.!)^ MSE3-?]!F'KQ;%5F^DHU3\4XI/E*:\=@J*7!P@ M1MIOW[X^;Q\?_/RO'W]X_[=VN]6GQ/8L:+=&B];UUF"OQ'^LPU?B.W=!T63*6W^__$?KY.CH;?OD MZ/BL]=]^__?N;S=?+__SRY>SL_Z@?_++X./_#EL/#P^'T)X`ZO=V:)%9J]V6 M(CD(?W\G_QD!!EM"&L?\Y[?$\O72Z+*E+"'_UUX5 M:\M'[>.3]NGQX2.S0X*.D?/4C4LY[TC`CMZ<'H7*R%9RJA^KL@3@^/S\O.-_ M&RXMFK/Y4_%PZZ\[P9>1TBA%G"=0!9$O`B8I<>``CEOR[^=!+UGACORV@VSZ M[8I8W@QBOOK;Q?8UYH@O>GA,Z,SGYF7+U^(=7[CPXB5#,]>!JV=3"L<7+V7C M[57C$O6?M-ONK$5W*62BF/_\5CS8Z!8^L2&2 M")W*#U+\T_;1\=)%?A*/O@7=#^`$R5XQOP,S&!%862PL8)C$+MT4%E!KU:3X MZ#-XH+3M98F.*V(BYFUKBAQ[57M,R2P'@"LA2(H.+8\):8@K*P+GH$6H#6D0 MSTO!?Z7()]%L`NX;7]<,[TW5DG$^*1OG/J2("!WL*\#3`-\L5U/D(\HF4W!: M%@5=(9(MQ;IQP"0!^LWO:P9Y1+EDJ,_*@CH0^U*(0X'3$^_/QU_A0AG6H^5J M!KU"V60*7I=%P:5'I:(WB%G`^3<$5!USE$5K1H1:Y60NWI3L#F0V(WC(B?5] M.!7*LWN/RW&TG+*I?2.M4LWXT8$AF:E_ELM4WQLYR+IQ"(@.GI/+U)*'#263 M87];+NPWR('T4CCLA%#UVV*S5"VACRB:#/YYR=$I")X#Z!+*A2L.!8X>4\>E MY.*UI$.ENF)J=E0N,5^(XPD4:6`U:D:BY6I)14Q9!0>ES8\#L;Y"Q_D5DP<\ MA(`1#.T>8QZD2BY4Y6O)B5)Y!3>ESZG7`[X;\23)0U0E:\:'4F$%$Z5-K3<% M"Z;]>ER$R]::C0VE%7P\S;_?=V)*WHH'6R^G7Q(Q[<0,VA^`(Q?FAU,(.=MV M`5W1VCZ7S!5=%K'=,6`CWPP\UIX`X`8&#!W.5D^BEKQ\_*W+F.ANZ@+RWI?#MT;U%8(0F+H MD1'&M:L;SY`^$'M:2]\)AWHOWY0*=>))\S5<>&6]0.RR+.)ASOI@`48.%(8E MGE`/VG$M5`$N1PO&/)2%0O:]>@@C7-=:Y.&@6Q8L;C'U=,`7Z% M:PQ=VT:!.'V`[!Z^!"[B4K;D*8ZBM/%4*-54,%+AVL(5G$.'N'+3;\C!!%YC M#JE+D1SJC9&%N!CG>3//'[-?>13A2;2&@KP=-&P\S[L`3V$2%:Y0Q-^JVD,' M\RE+4DY!086K"%G+R%NNHYM/3[;B"K+.]YZ'(%/HH'1<=C^^=R$-#I$63DA0 M-%M*9H*B[VIL?B!"(_9@5I)"K%A%+KJ2(T/,JEU.A6K8Z=:JJ#,06NYJ>'\; M**J4S1=,O`<9]$M6Q<_2GO'D^M&5QIYE5^KR-6`P15GCDA\&`D&A_53$]]!H M:"FXTIO2ZM2`H`REC4N7Z%,RAHSY\MQ`992+%:L!%7'5C$NGN!^+V8.(H/+6 M"F$@/H*JL)54M`8L)*MH7%+$1XA%9'7D'K,]0]@_YL[1'*:'JZQ:->`G4W'C MLB1B[T#=%WT=Z$A0SKC,AAZVR`S>$L9NA'YBDB'D]83(ZYF%>HLTJV(-*-)1 MW[ATA7L^A320/&M\G%"R!JPD*FA()G?E):Y MJE&Q!B3IJ&]>;D'(M+)]I@XT;"AD7B+!%6)6$%6A_114NS.9,G8_[MI_>(S[ M=^.0/D6$!H>7/@*$94B^QZ*V2QAP/L`QH3#0\A-X5.U>[*6O&MC`GD`V+U$B M5=&0)ZQ>Z(%J_K;>_3BQ\AT4-;8#8,B2BYS( M\3A4&7Y6K1K0DJFX>:D>7Z&\Y!;:W;F(H!-XY\U&D-Z/@QN+_`L0;%\+!6G: MU6O`GCX46>D9I6PWRV.L-PYYV.UN\[K5TC>;UUU7=$H#8:FU"96IV(^WYVCCZ,FFVL8=L=?7 M,FE%<6?6F=IX4PQA)T`;MY_N)TD%[ZP@QS"8E`?OLN!S]/1.6CY?SI8:81M; M06CD4"/HBRINW'Y^_/3<->-H)M.";SSN41C*"9'* MZ)\ES&JG$?QN`9]YB00`X7L:K)(&6QQ!T,%#;\20C4#L>M`\-1M!LQ9$QJ4= M1(WSRH-R_=)?TMP\ZZSIU"D--(+F/(`9E^/0X(W:W;"[_59NA5D0\1>,;XUK MU8-S"SA\VEW`E3'[*MIJ(^RA,+3&Y6HD7H40OK=$VQRB]1I*>`P>\U(Y_K*7 M\NR&\YU=W%-E>DF?0A<@>YE@F7Y;2'+91G"I@,&\!(Z&W\FSQVBL>V]/A6M9 M^MH77OIN!M%Y`#,O9T,A?0_/(=O%?EQ:0TVF/Q5`\[))PI-'?YJ0>MI=5;H1 MA"JA,"^O1-_V"CMM,[C-`YAYUX,HI+]!&&!K![$ZK:$FTY\*H'E7E(0#E-PQ MIV@D$]_2;W3*J-0(>K.`R;K`I%HJ0W/WQ14-EC"JZ'P.[49!.XR+25WH%U=[MX]OQ7\A"A+(J&WF]K8U<8[M2"QEZKNOXAR*`LSH3D?(S MC=%\78B.^ M6,L6AE9BK5!&IV:]?%@+BTH]^'2()AB-D04P7^8JRD-^Q$&6&(;LQJ4S^BC/ MQS,$>7;Z[6?K:1CI^=>_MW MN0#R5FXLCH#U/63!^LZ=IX5Z.7W)(#J`;A382SF"A=0-#JY]17SZ=2JSOV(%V?6C3`X[ M/NI#:D%YA6G\I\HRXT<%DM0L#E7!5<7QS!LQ^*[VZ\$F^VS!@6[?LY M>A7(%]C$,C/&*,O7+!*H]39X8?$S$Z%K=541*W.Y4=&S*8N0"O$JRGZ7W2]T M@X*J=$4!81-)A8;>/:F>PK_O7!;M"&^WJ]0D=^H@8'%2$T'#C.258?+2" M>4V9L453$E-"C*:XSY$FM_!W\"$5UD5$7N4YI9S-U"?RY$?(S-W1^-G5W0:< M;3HV8$,-)8U,FK5)UADZK]U;%A^(_\9`0;%D_\#4$L# M!!0````(`.QC$T4']HH):04```(D```1`!P`<')T="TR,#$T,#8S,"YX_-3=7@+``$$)0X```0Y`0``[5IM;]LV$/[<`?L/7+ZH!2++ MLITL,>P6KIL$*=+&L-.MV#`4M$391"52):F\_/L>]6;)L9BW=2@6?PHIWCUW MQ^=X.H<:O+F.0G1)A*2<#2VWU;8081[W*5L,+2JY?7"P=VB[UIO7O_XR^,VV MT41P/_&(C^8WZ.C=R6@J$ZH(DCQ05UB0733R+S'3`F,>Q8DB`ITRQB^Q`@MR M%R9>:Q?6XAM!%TN%7HY?H4Z[?6!WVFX/_3V9?!Y]./YS_-?[/WJ]R732>3\] M^:>%KJZN6L1?8)%::WD\0K:M79+>DD08011,#JVE4G'?<;3T5;?%Q<(!:-?Y M_.%LELI9F6`_D?8"X[A4"+"@KS.*8LX.GDQ4![UR]< MG)(`I9O55SY(&L4AV+91;9`((CXE0E,AR?W>F!R2CQ2>RXX@Z&7%@=92.T@Z@]W?A!V M%FH>ZRK;7[?AA=!M(QNM;,)$FT5=&%1,HY4-5,#V46:^ME9S`+TL9%\-G'7C M59\22?QS]CH=KQ>87#,7:=*JG^'[Z:REU@:E_%&1'O]5RGR2Y#PXDHI&6)$G MID@#EBDEW">D!)A#/$"EP6T*-*5`;TK`,/$G6*B;"X&9Q%[:%S;QW*Q@(+/] M^V8R>S#(\>Q8`Z(JXI:JVLYW3CAD^9A#71.LB9ZZD(F2O\PAZZ.*-92;V];+%?VP/3YA@#V#T+*. MXCP88[D\#OE5A=L[Y$Q',>U^2C48EUBKIU*_T#0<2O&>/2WUH^26.W9,&?SP MI3A<[5S3^3,KF0AK.&ENC;H2M$+BEK8'-(UOL:3>&9=R0L281Q%GLR46Y&F= MZ%V@I@+;>4)+FMI%+T%3OD)@&V7&46I]6V\?ER&/2P'CT=Y_-,=;YFH<[,UP M"#_Z)E#Z##5X3H0,Q]E4*B"M:6G=@3V9XI[7R>)\)98DM%"D+17:#HQ M3>(F@@XW'YW]M.T$-%3`H1+OV9-4-G)O<:BO4F9+0M2F?K^^;J+!;>[SO:,;/QY>QX3@=?^77B7 MH.F`=.[[0WB%]_\A9N!4;E5A4KMR'=`HYD*A[';]C'OIBN$&6,_LXAK8UH]L MMV-WW=:U]"W$;MU*&^Z0G8N,G!#5KMW6,WT@T.)?:V:CHD%#)XHF]@LH\OL,5 MX^<5)E?6=?2@P7C^)0/"`,GVR48?@=02P$"'@,4````"`#L8Q-%]AA0]M8:``!8E@`` M$0`8```````!````I($`````<')T="TR,#$T,#8S,"YX;6Q55`4``]Q[\U-U M>`L``00E#@``!#D!``!02P$"'@,4````"`#L8Q-%;P\?+(8%```!/0``%0`8 M```````!````I($A&P``<')T="TR,#$T,#8S,%]C86PN>&UL550%``/<>_-3 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[&,315#$M.6)`P``JQD``!4` M&````````0```*2!]B```'!R='0M,C`Q-#`V,S!?9&5F+GAM;%54!0`#W'OS M4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.QC$T6JM]Q:K1,``#/G```5 M`!@```````$```"D@`L``00E#@``!#D!``!02P$"'@,4````"`#L8Q-%D'XKK-H,``!@O0`` M%0`8```````!````I('*.```<')T="TR,#$T,#8S,%]P&UL550%``/< M>_-3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`[&,310?VB@EI!0```B0` M`!$`&````````0```*2!\T4``'!R='0M,C`Q-#`V,S`N>'-D550%``/<>_-3 E=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``*=+```````` ` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 5 - Sale of Patents
6 Months Ended

Jun. 30, 2014

Notes

Note 5 - Sale of Patents
NOTE 5 – SALE OF PATENTS

On January 31, 2011, Protect Pharmaceutical Corporation (the “Company”) finalized and closed a Patent Purchase Agreement (the “Agreement”) with Grünenthal GmbH (“Grünenthal”), a company organized under the laws of Germany. Pursuant to the terms of the Agreement, the Company sold to Grünenthal all of the Company’s rights title and interest in and to certain inventions described and claimed in certain patents and patent applications (collectively “the Patents”), including without limitation, all extensions, continuations, provisions, derivatives and related applications thereof. The Patents relate to Opioid Formulations and Methods of treating acute and chronic pain.
In exchange for the Patents, Grünenthal paid the Company $1,600,000. The Company originally acquired the subject Patents sold to Grünenthal, together with other inventions and patents, in February 2010 pursuant to a Patent Acquisition Agreement with Nectid, Inc. (“Nectid”), a privately held New Jersey company. Under the terms of the Patent Acquisition Agreement and Addendum, the Company agreed that in the event the Company sold out right any of the patents acquired from Nectid without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Company. Accordingly, the Company realized 40%, or $640,000 from the proceeds of the sale and the balance will be paid to Nectid. The Company retains all other inventions, patents and technologies initially acquired from Nectid.

Note 5 - Sale of Patents	6 Months Ended
Jun. 30, 2014
Notes
Note 5 - Sale of Patents	NOTE 5 – SALE OF PATENTS On January 31, 2011, Protect Pharmaceutical Corporation (the “Company”) finalized and closed a Patent Purchase Agreement (the “Agreement”) with Grünenthal GmbH (“Grünenthal”), a company organized under the laws of Germany. Pursuant to the terms of the Agreement, the Company sold to Grünenthal all of the Company’s rights title and interest in and to certain inventions described and claimed in certain patents and patent applications (collectively “the Patents”), including without limitation, all extensions, continuations, provisions, derivatives and related applications thereof. The Patents relate to Opioid Formulations and Methods of treating acute and chronic pain. In exchange for the Patents, Grünenthal paid the Company $1,600,000. The Company originally acquired the subject Patents sold to Grünenthal, together with other inventions and patents, in February 2010 pursuant to a Patent Acquisition Agreement with Nectid, Inc. (“Nectid”), a privately held New Jersey company. Under the terms of the Patent Acquisition Agreement and Addendum, the Company agreed that in the event the Company sold out right any of the patents acquired from Nectid without first undertaking any development of the patents, the proceeds from such sale would be divided, 60% to Nectid and 40% to the Company. Accordingly, the Company realized 40%, or $640,000 from the proceeds of the sale and the balance will be paid to Nectid. The Company retains all other inventions, patents and technologies initially acquired from Nectid.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for sale leaseback transactions. Includes the elements of a transaction involving the sale of property to another party and the lease of the property back to the seller.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6452660&loc=d3e36991-112694

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6456341&loc=d3e50796-112755

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 40

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6456377&loc=d3e50824-112756

+ Details

Name: us-gaap_SaleLeasebackTransactionDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\S,F%D861B,5\V,#0S7S1B969?86,X,5\V-&$T M-V-C-&1B,&0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO M=&5?,U]3:6=N:69I8V%N=%]!8V-O=6YT:6YG7S(\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E M;%=O5]4#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O6QE#I! M8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0 M#I0#I0&UL M/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@ M<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S,R861A9&(Q7S8P-#-?-&)E9E]A8S@Q7S8T830W8V,T9&(P M9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,F%D861B,5\V,#0S M7S1B969?86,X,5\V-&$T-V-C-&1B,&0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)S$P+5$\'0^2G5N(#,P+`T*"0DR,#$T M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$4-E;G1R86Q);F1E>$ME>3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)S`P,#$T.3,U,C8\'0^)RTM M,3(M,S$\4-O;6UO;E-T;V-K4VAA5!U8FQI8T9L;V%T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD M(#0T+#4W,RPP,3(\49I;&5R0V%T96=O59O;'5N=&%R>49I;&5R'0^)TYO/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^)S(P,30\7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO6%B;&4@+2!R96QA=&5D('!A6%B;&4@ M+2!R96QA=&5D('!A'!E;G-E3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\S,F%D861B,5\V,#0S7S1B969?86,X,5\V M-&$T-V-C-&1B,&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S)A M9&%D8C%?-C`T,U\T8F5F7V%C.#%?-C1A-#=C8S1D8C!D+U=O'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5C=71I=F4@8V]M<&5N'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'!E M;G-E3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S6%B;&4\+W1D/@T*("`@("`@ M("`\=&0@8VQA'0^ M)SQS<&%N/CPO'0^ M)SQS<&%N/CPO2!O9F9I8V5R/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^)SQS<&%N/CPO6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA6UE;G0@;V8@2!P87EA8FQE M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2`H57-E9"!I;BD@1FEN86YC:6YG($%C=&EV M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SPA+2UE9W@M+3X\<')E M('-T>6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y/CQB/DY/5$4@,2`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`T,U\T8F5F7V%C M.#%?-C1A-#=C8S1D8C!D+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SPA+2UE9W@M+3X\<')E('-T>6QE M/3-$=&5X="UA;&EG;CIJ=7-T:69Y/CQB/DY/5$4@,B`M($=/24Y'($-/3D-% M4DX\+V(^/"]P'0M86QI9VXZ:G5S=&EF>3Y4 M:&4@0V]M<&%N>28C,30V.W,@9FEN86YC:6%L('-T871E;65N=',@87)E('!R M97!AF%T:6]N(&]F(&%S2!T;R!S965K(&$@;65R9V5R('=I=&@@86X@97AI'1087)T7S,R861A9&(Q7S8P M-#-?-&)E9E]A8S@Q7S8T830W8V,T9&(P9`T*0V]N=&5N="U,;V-A=&EO;CH@ M9FEL93HO+R]#.B\S,F%D861B,5\V,#0S7S1B969?86,X,5\V-&$T-V-C-&1B M,&0O5V]R:W-H965T'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA"TM/CQP'0M86QI9VXZ:G5S=&EF>3ML M:6YE+6AE:6=H=#IN;W)M86P^/'4^57-E(&]F($5S=&EM871E6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.VQI;F4M:&5I9VAT.FYO M2!W:71H(&=E;F5R86QL>2!A8V-E<'1E9"!A8V-O=6YT M:6YG('!R:6YC:7!L97,@'0M86QI9VXZ:G5S=&EF>3ML:6YE+6AE:6=H=#IN;W)M86P^/'4^0F%S M:6,@*$QO'0M86QI9VXZ:G5S=&EF>3ML:6YE+6AE:6=H=#IN;W)M86P^0F%S:6,@ M;&]S2!D:79I9&EN9R!T:&4@ M0V]M<&%N>28C,30V.W,@;F5T(&QO6QE/3-$;6%R9VEN+6)O='1O;3HP M:6X[;6%R9VEN+6)O='1O;3HN,#`P,7!T.VQI;F4M:&5I9VAT.FYO6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.VQI;F4M M:&5I9VAT.FYO6QE/3-$=&5X="UA;&EG;CIJ=7-T:69Y.VQI M;F4M:&5I9VAT.FYO2!H87,@979A;'5A=&5D(')E M8V5N="!A8V-O=6YT:6YG('!R;VYO=6YC96UE;G1S(&%N9"!T:&5I28C,30V.W,@9FEN86YC M:6%L('!O'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SQS<&%N/CPO2!4'0M86QI9VXZ:G5S M=&EF>3Y4:&4@0V]M<&%N>2!O=V5D('1R861E(&%C8V]U;G1S('!A>6%B;&4@ M=&\@82!R96QA=&5D('!A2!A;B!E;G1I='D@=&AA="!I'0M86QI9VXZ:G5S=&EF>3Y4:&4@0V]M<&%N>2!H87,@2!A M6%B;&5S+B!!2!P87EA8FQE(&]U='-T86YD:6YG(&)A;&%N8V4@=&]T86QE M9"`D,S0L-#,Y("8C,38P.V%N9"`D,C0L.30P("XF;F)S<#M4:&5S92!P87EA M8FQE6QE/3-$8F%C M:V=R;W5N9#IW:&ET93Y#;VYT6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[=&5X="UA;&EG;CIJ=7-T:69Y/CQF;VYT('-T>6QE/3-$8F%C:V=R;W5N M9#IW:&ET93Y$=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@ M,C`Q-"!A;F0@,C`Q,RP@82!R96QA=&5D+7!A3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\S,F%D861B,5\V,#0S7S1B969?86,X,5\V-&$T M-V-C-&1B,&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S)A9&%D M8C%?-C`T,U\T8F5F7V%C.#%?-C1A-#=C8S1D8C!D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6QE/3-$;6%R9VEN M+7)I9VAT.BTN-6EN.W1E>'0M86QI9VXZ:G5S=&EF>3X\8CXF(S$V,#LF(S$V M,#LF(S$V,#LF(S$V,#LF(S$V,#L@/"]B/CPO<')E/CQP2`S,2P@,C`Q,2P@4')O=&5C M="!0:&%R;6%C975T:6-A;"!#;W)P;W)A=&EO;B`H=&AE("8C,30W.T-O;7!A M;GDF(S$T.#LI(&9I;F%L:7IE9"!A;F0@8VQO2`D,2PV,#`L,#`P+B!4:&4@0V]M<&%N>2!O2!C M;VUP86YY+B8C,38P.R!5;F1E2!A9W)E960@=&AA="!I;B!T:&4@979E;G0@=&AE($-O;7!A;GD@2P@=&AE($-O;7!A;GD@2!A8W%U M:7)E9"!F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SPA+2UE9W@M+3X\<')E('-T>6QE/3-$=&5X M="UA;&EG;CIJ=7-T:69Y/CQB/DY/5$4@/"]B/CQB/C8\+V(^/&(^("T@4U1/ M0TL@4%520TA!4T4@04=2145-14Y4/"]B/CPO<')E/B`\<"!S='EL93TS1&UA M'0M86QI9VXZ:G5S M=&EF>3X\9F]N="!S='EL93TS1&)A8VMG3PO9F]N M=#X\9F]N="!S='EL93TS1&)A8VMG6QE/3-$8F%C:V=R;W5N9#IW:&ET93YS(&-O;6UO;B!S=&]C M:R!U<"!T;R!A;B!A9V=R96=A=&4@=F%L=64@;V8@)#$P(&UI;&QI;VX@9&]L M;&%R6QE/3-$8F%C:V=R;W5N9#IW:&ET M93XF;F)S<#L\+V9O;G0^/"]P/B`\<"!S='EL93TS1&UA3XF;F)S<#L\ M+W`^(#QP('-T>6QE/3-$;6%R9VEN.C!I;CMM87)G:6XM8F]T=&]M.BXP,#`Q M<'0[=&5X="UA;&EG;CIJ=7-T:69Y/B9N8G-P.SPO<#X@/'`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`\<"!S='EL M93TS1'1E>'0M86QI9VXZ:G5S=&EF>3ML:6YE+6AE:6=H=#IN;W)M86P^)FYB M'0M86QI9VXZ:G5S=&EF>3ML:6YE+6AE M:6=H=#IN;W)M86P^5&AE($-O;7!A;GD@:6YT96YD960@=&\@=7-E('1H92!P M'0M86QI9VXZ:G5S=&EF>3ML:6YE+6AE:6=H=#IN M;W)M86P^)FYB'0M86QI9VXZ:G5S=&EF M>3ML:6YE+6AE:6=H=#IN;W)M86P^/&9O;G0@'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0M86QI9VXZ:G5S=&EF>3ML:6YE+6AE:6=H=#IN M;W)M86P^)FYB'0M86QI9VXZ:G5S=&EF M>3ML:6YE+6AE:6=H=#IN;W)M86P^26X@86-C;W)D86YC92!W:71H($%30R`X M-34M,3`L($-O;7!A;GD@;6%N86=E;65N="!R979I97=E9"!A;&P@;6%T97)I M86P@979E;G1S('1H'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0M86QI9VXZ:G5S=&EF>3ML:6YE+6AE:6=H=#IN;W)M86P^5&AE('!R M97!A'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'0^)SPA+2UE9W@M+3X\<"!S M='EL93TS1'1E>'0M86QI9VXZ:G5S=&EF>3ML:6YE+6AE:6=H=#IN;W)M86P^ M/'4^0F%S:6,@*$QO'0M86QI9VXZ:G5S=&EF>3ML:6YE+6AE:6=H=#IN;W)M86P^ M0F%S:6,@;&]S2!D:79I9&EN M9R!T:&4@0V]M<&%N>28C,30V.W,@;F5T(&QO3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\S,F%D861B,5\V,#0S7S1B969?86,X,5\V M-&$T-V-C-&1B,&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S)A M9&%D8C%?-C`T,U\T8F5F7V%C.#%?-C1A-#=C8S1D8C!D+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\S,F%D861B,5\V,#0S7S1B969?86,X,5\V-&$T-V-C-&1B M,&0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S)A9&%D8C%?-C`T M,U\T8F5F7V%C.#%?-C1A-#=C8S1D8C!D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO'0^)SPA+2UE9W@M+3X\ M<"!S='EL93TS1&UA6QE/3-$8F%C:V=R;W5N9#IW:&ET93Y#;VYT6QE/3-$;6%R9VEN.C!I;CMM M87)G:6XM8F]T=&]M.BXP,#`Q<'0[=&5X="UA;&EG;CIJ=7-T:69Y/CQF;VYT M('-T>6QE/3-$8F%C:V=R;W5N9#IW:&ET93Y$=7)I;F<@=&AE('-I>"!M;VYT M:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@,C`Q,RP@82!R96QA=&5D+7!A M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,F%D861B,5\V M,#0S7S1B969?86,X,5\V-&$T-V-C-&1B,&0-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,S)A9&%D8C%?-C`T,U\T8F5F7V%C.#%?-C1A-#=C8S1D M8C!D+U=O&UL#0I#;VYT96YT+51R86YS9F5R M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E M>'0O:'1M;#L@8VAA&UL;G,Z;STS M1")U'1087)T7S,R861A9&(Q @7S8P-#-?-&)E9E]A8S@Q7S8T830W8V,T9&(P9"TM#0H` ` end XML 17 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 4 - Related-party Transactions
6 Months Ended

Jun. 30, 2014

Notes

Note 4 - Related-party Transactions
NOTE 4 – RELATED-PARTY TRANSACTIONS
The Company owed trade accounts payable to a related party in the amount of $21,714, and $23,939, as of June 30, 2014, and December 31, 2013, respectively. These amounts related to accounting and consulting services provided by an entity that is partially owned by a Company officer.
The Company has recorded advances from related parties and expenses paid by related parties on behalf of the Company as related party payables. As of June 30, 2014 and December 31, 2013, respectively, the related party payable outstanding balance totaled $34,439 and $24,940 . These payables are non-interest bearing, unsecured, and are due on demand.

Contributed Capital

During the six months ended June 30, 2014 and 2013, a related-party has contributed various administrative services to the Company. These services have been valued at $3,000 for the six month periods then ended.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Balance Sheets (USD $)
323 Months Ended

Jun. 30, 2014

Dec. 31, 2013

ASSETS

Cash $ 591 $ 681

Total Current Assets 591 681

TOTAL ASSETS 591 681

Accounts payable and accrued expenses 61,954 60,104

Accounts payable - related parties 165,476 23,939

Notes payable - related parties 34,439 24,940

Other accrued expenses 486,826

Total Current Liabilities 604,933 595,809

TOTAL LIABILITIES 604,933 595,809

Common stock; 100,000,000 shares authorized,at $0.005 par value, 44,573,012 and 44,573,012 shares issued and outstanding, respectively 222,865 222,865

Additional paid-in capital 8,357,980 8,354,980

Deficit accumulated during the development stage (9,185,187) (9,172,973)

Total Stockholders' Deficit (604,342) (595,128)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 591 $ 681

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount for accounts payable to related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 7

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The amount for notes payable (written promise to pay), due to related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 7

+ Details

Name: us-gaap_NotesPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 19 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 2 - Going Concern
6 Months Ended

Jun. 30, 2014

Notes

Note 2 - Going Concern
NOTE 2 - GOING CONCERN
The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company does not have significant cash or other material assets, nor does it have an established source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. It is the intent of the Company to seek a merger with an existing, operating company. In the interim, shareholders of the Company have committed to meeting its minimal operating expenses

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

If there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date), disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 948

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6490092&loc=d3e47214-110998

+ Details

Name: us-gaap_LiquidityDisclosureGoingConcernNote

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 21 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 3 - Significant Accounting Policies
6 Months Ended

Jun. 30, 2014

Notes

Note 3 - Significant Accounting Policies
NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basic (Loss) per Common Share

Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of June 30, 2014 and 2013.

Recent Accounting Pronouncements

The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Statements of Operations (USD $)
3 Months Ended 6 Months Ended 323 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

REVENUES

Research and development $ 1,353,540

Professional Fees 8,630 9,727 9,125 11,313 1,507,868

Executive compensation 1,500 1,500 3,000 3,000 5,897,730

General and administrative 45 46 89 90 447,209

Total Expenses 10,175 11,273 12,214 14,403 9,206,347

LOSS FROM OPERATIONS (10,175) (11,273) (12,214) (14,403) (9,206,347)

Gain on sale of patents (640,000)

Total Other Income 640,000

LOSS BEFORE DISCONTINUED OPERATIONS (10,175) (11,273) (12,214) (14,403) (8,566,347)

LOSS FROM DISCONTINUED OPERATIONS (4,340,551)

PROFIT LOSS $ (10,175) $ (11,273) $ (12,214) $ (14,403) $ (12,906,898)

BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK $ 0.00 $ 0.00 $ 0.00 $ 0.00

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING 44,573,012 44,573,012 44,573,012 44,573,012

X

- Definition

Pretax adjustment to an amount previously reported in discontinued operations that is directly related to the disposal of the component in a prior period. Examples of circumstances leading to such adjustments include the resolution of contingencies relating to the terms of the disposal transaction or relating to the operations of the component prior to its disposal, and the settlement of certain employee benefit plan obligations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1012-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1510-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e1020-107759

+ Details

Name: us-gaap_DiscontinuedOperationAmountOfAdjustmentToPriorPeriodGainLossOnDisposalBeforeIncomeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Other income (loss) amounts, net of tax expense or benefit, relating to a disposal group that is classified as a component of the entity, exclusive of the following elsewhere enumerated categories: income (loss) from operations during the phase-out period, gain (loss) on disposal, provision (or any reversals of earlier provisions) for loss on disposal, and adjustments of a prior period gain (loss) on disposal.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6892542&loc=d3e957-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

+ Details

Name: us-gaap_DiscontinuedOperationAmountOfOtherIncomeLossFromDispositionOfDiscontinuedOperationNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_IncomeLossFromContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OfficersCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.4)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 4

-Article 7

+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section 45

-Paragraph 3

-Subparagraph (k)

-URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849

+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=31814832&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e2646-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesIssuedBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 23 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information (USD $)
6 Months Ended

Jun. 30, 2014

Document and Entity Information:

EntityRegistrantName PROTECT PHARMACEUTICAL Corp

DocumentType 10-Q

DocumentPeriodEndDate Jun. 30, 2014

AmendmentFlag false

EntityCentralIndexKey 0001493526

CurrentFiscalYearEndDate --12-31

EntityCommonStockSharesOutstanding 44,573,012

EntityPublicFloat $ 44,573,012

EntityFilerCategory Smaller Reporting Company

EntityCurrentReportingStatus No

EntityVoluntaryFilers No

EntityWellKnownSeasonedIssuer No

DocumentFiscalYearFocus 2014

DocumentFiscalPeriodFocus Q2

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.

+ References

No definition available.

+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_DocumentAndEntityInformationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Condensed Statements of Cash Flows (USD $)
6 Months Ended 323 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

OPERATING ACTIVITIES

Net loss $ (12,214) $ (14,403) $ (12,906,898)

Common stock issued for services 9,904,653

Services contributed by officers 3,000 3,000 15,000

Common stock issued for research and development costs 1,250,000

Loss from disposition of subsidiary 564,300

Expenses paid on behalf of the Company 9,499 4,860 99,958

Gain on sale of patents (640,000)

Accounts payable 1,850 (1,521) 61,955

Accounts payable - related parties 165,476 7,975 165,476

Prepaid expenses 491,667 491,667

Other accrued expenses 486,826

Net Cash Provided by Operating Activities (90) (89) (507,062)

Proceeds from sale of patent 640,000

Net Cash Used in Investing Activities 640,000

Capital contributed by officer 13,046

Proceeds from related party payable 100

Repayment of related party payable (145,493)

Net Cash Provided by (Used in) Financing Activities (132,347)

NET INCREASE (DECREASE) IN CASH (90) (89) 591

CASH AT BEGINNING OF PERIOD 681 860

CASH AT END OF PERIOD 591 771 591

Common stock issued for prepaid services $ 750,000

X

- Definition

Amount for accounts payable to related parties.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.17)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 7

+ Details

Name: us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs related to services rendered by an entity during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Subparagraph g

-Article 9

+ Details

Name: us-gaap_GainOrLossOnSaleOfStockInSubsidiary

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity. This element is used when there is no other more specific or appropriate element.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseDueFromOtherRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) in standardized measure of discounted future net cash flow as a result of change in estimated future development costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 932

-SubTopic 235

-Section 50

-Paragraph 31

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=8451039&loc=d3e62455-109447

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 932

-SubTopic 235

-Section 50

-Paragraph 35

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=8451039&loc=d3e62500-109447

+ Details

Name: us-gaap_IncreaseDecreaseInEstimatedFutureDevelopmentCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_OtherNoncashExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 340

-SubTopic 10

-Section 05

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6386993&loc=d3e5879-108316

+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cash inflow associated with the amount received by a corporation from a shareholder during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromContributedCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from other equity not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromOtherEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the period in the number of shares issued.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 25 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 3 - Significant Accounting Policies: Use of Estimates (Policies)
6 Months Ended

Jun. 30, 2014

Policies

Use of Estimates
Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 6 - Subsequent Events
6 Months Ended

Jun. 30, 2014

Notes

Note 6 - Subsequent Events
NOTE 6 – SUBSEQUENT EVENTS

In accordance with ASC 855-10, Company management reviewed all material events through the date of this report and determined that there are no additional material subsequent events to report.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 4 - Related-party Transactions: Contributed Capital (Policies)
6 Months Ended

Jun. 30, 2014

Policies

Contributed Capital
Contributed Capital

During the six months ended June 30, 2014 and 2013, a related-party has contributed various administrative services to the Company. These services have been valued at $3,000 for the six month periods then ended.

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's capital units or capital shares, including the value of capital units or capital shares, units authorized, units outstanding and other information necessary to a fair presentation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-04.16)

-URI http://asc.fasb.org/extlink&oid=6488278&loc=d3e603758-122996

+ Details

Name: us-gaap_ScheduleOfCapitalUnitsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 3 - Significant Accounting Policies: Basic (loss) Per Common Share (Policies)
6 Months Ended

Jun. 30, 2014

Policies

Basic (loss) Per Common Share
Basic (Loss) per Common Share

Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted earnings per share is calculated by dividing the Company’s net income available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There are no such common stock equivalents outstanding as of June 30, 2014 and 2013.

X

- Definition

Disclosure of the methodology and assumptions used in the reconciliation of earnings per share, which may include the individual income and share amount effects of all securities that affect earnings per share, the effect that has been given to preferred dividends in arriving at income available to common stockholders in computing basic earnings per share, securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic EPS in the future that were not included in the computation of diluted EPS because to do so would have been antidilutive for the period(s) presented and a description of any transaction that occurs after the end of the most recent period but before issuance of the financial statements that would have changed materially the number of common shares or potential common shares outstanding at the end of the period if the transaction had occurred before the end of the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_EarningsPerShareReconciliationDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 3 - Significant Accounting Policies: Recent Accounting Pronouncements (Policies)
6 Months Ended

Jun. 30, 2014

Policies

Recent Accounting Pronouncements
Recent Accounting Pronouncements

The Company has evaluated recent accounting pronouncements and their adoption has not had or is not expected to have a material impact on the Company’s financial position or statements.

X

- Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PolicyTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 1 - Condensed Financial Statements
6 Months Ended

Jun. 30, 2014

Notes

Note 1 - Condensed Financial Statements
NOTE 1 - CONDENSED FINANCIAL STATEMENTS
The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at June 30, 2014, and for all periods presented herein, have been made.
Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2013 audited financial statements. The results of operations for the periods ended June 30, 2014and 2013 are not necessarily indicative of the operating results for the full years.

X

- Definition

The entire disclosure for condensed financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 10

-Paragraph f

-Article 3

+ Details

Name: us-gaap_CondensedFinancialStatementsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Note 6 - Stock Purchase Agreement
6 Months Ended

Jun. 30, 2014

Notes

Note 6 - Stock Purchase Agreement
NOTE 6 - STOCK PURCHASE AGREEMENT

On June 17, 2011, Protect Pharmaceutical Corporation finalized the execution of an Investment Agreement with Kodiak Capital Group, LLC, a Delaware limited liability company. The Agreement provides the Company with an equity line whereby the Company can sell to Kodiak, from time-to-time, shares of the Company’s common stock up to an aggregate value of $10 million dollars over a two-year period. As part of the agreement, the Company will file with the SEC a registration statement under the Securities Act of 1933 to register the common stock that may be sold to Kodiak pursuant to the Agreement.

Under the terms of the Agreement, The Company has the right to deliver to Kodiak a “put notice” stating the dollar amount of common shares we intend to sell to Kodiak, up to $250,000. The amount that the Company is entitled to sell to Kodiak under any single put notice will be equal to, at Kodiak's election, either: (i) 200% of the average daily volume (U.S. market only) of the common stock for the three trading days prior to the put notice, multiplied by the average of the three daily closing bid prices immediately preceding the put notice date; or (ii) up to $250,000.

The Company cannot submit a new put notice until after the closing of the previous notice. The purchase price for the shares pursuant to the put notice will be equal to 92% of the lowest closing best bid price of the common stock during the five trading days after the put notice is delivered. The shares must be paid for and share certificates delivered within the “pricing period,” which is seven days from the date the put notice is delivered.

The Company has the option to specify a floor price for any put notice. In the event our shares fall below the floor price, the put will be temporarily suspended. The put will resume if, during the pricing period for that put, the common stock trades above the floor price.

The Company has agreed to pay to Kodiak an initial fee of 150,000 shares of common stock following execution of the Agreement. Also, the Company has agreed to pay Kodiak a commitment fee equal to 3% of the total amount of the commitment, payable as follows: (i) 25% on the first closing of a put notice; (ii) 25% on the second closing, (iii) 25% on the third closing; and (iv) 25% on the fourth closing or eight months from execution of the Agreement. The commitment fee is payable in Company common stock.

In connection with the Agreement, we entered into a Registration Rights Agreement with Kodiak, whereby the Company agreed to register with the SEC the shares to be issued pursuant to the Agreement. The Company must prepare and file within 90 days from the date of the Agreement, a registration statement under the Securities Act of 1933.

The Company intended to use the proceeds from the sale of common stock pursuant to the Agreement for general corporate and working capital purposes and acquisitions of assets, businesses or operations, or for other purposes that the board of directors deems to be in the best interest of the Company.

As of December 31, 2013 the Company has not initiated any activity with respect to the Investment Agreement other than the initial issuance of 150,000 common shares. The Company has not registered with the SEC the shares to be issued to Kodak. The Agreement expired on June 17, 2014.

X

- Details

Name: us-gaap_DisclosureTextBlockAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure, as of the balance sheet date, of the amount at risk under repurchase agreements with any individual counterparty or group of related counterparties which exceeds 10 percent of stockholders' equity. Includes the name of each counterparty or group of related counterparties, the amount at risk with each, and the weighted average maturity of the repurchase agreements with each. The amount at risk under repurchase agreements is defined as the excess of carrying amount (or market value, if higher than the carrying amount or if there is no carrying amount) of the securities or other assets sold under agreement to repurchase, including accrued interest plus any cash or other assets on deposit to secure the repurchase obligation, over the amount of the repurchase liability (adjusted for accrued interest).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph m

-Subparagraph 1

-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(m)(1)(i)(B)(iii))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ScheduleOfRepurchaseAgreementCounterpartiesWithWhomRepurchaseAgreementsExceed10PercentOfStockholdersEquityTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 9 70 1 false 0 0 false 3 false false R1.htm 000000 - Document - Document and Entity Information Sheet http://prtt/20140630/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000010 - Statement - Condensed Balance Sheets Sheet http://prtt/20140630/role/idr_CondensedBalanceSheets Condensed Balance Sheets false false R3.htm 000020 - Statement - Condensed Statements of Operations Sheet http://prtt/20140630/role/idr_CondensedStatementsOfOperations Condensed Statements of Operations false false R4.htm 000030 - Statement - Condensed Statements of Cash Flows Sheet http://prtt/20140630/role/idr_CondensedStatementsOfCashFlows Condensed Statements of Cash Flows false false R5.htm 000040 - Disclosure - Note 1 - Condensed Financial Statements Sheet http://prtt/20140630/role/idr_DisclosureNote1CondensedFinancialStatements Note 1 - Condensed Financial Statements false false R6.htm 000050 - Disclosure - Note 2 - Going Concern Sheet http://prtt/20140630/role/idr_DisclosureNote2GoingConcern Note 2 - Going Concern false false R7.htm 000060 - Disclosure - Note 3 - Significant Accounting Policies Sheet http://prtt/20140630/role/idr_DisclosureNote3SignificantAccountingPolicies Note 3 - Significant Accounting Policies false false R8.htm 000070 - Disclosure - Note 4 - Related-party Transactions Sheet http://prtt/20140630/role/idr_DisclosureNote4RelatedPartyTransactions Note 4 - Related-party Transactions false false R9.htm 000080 - Disclosure - Note 5 - Sale of Patents Sheet http://prtt/20140630/role/idr_DisclosureNote5SaleOfPatents Note 5 - Sale of Patents false false R10.htm 000090 - Disclosure - Note 6 - Stock Purchase Agreement Sheet http://prtt/20140630/role/idr_DisclosureNote6StockPurchaseAgreement Note 6 - Stock Purchase Agreement false false R11.htm 000100 - Disclosure - Note 6 - Subsequent Events Sheet http://prtt/20140630/role/idr_DisclosureNote6SubsequentEvents Note 6 - Subsequent Events false false R12.htm 000110 - Disclosure - Note 3 - Significant Accounting Policies: Use of Estimates (Policies) Sheet http://prtt/20140630/role/idr_DisclosureNote3SignificantAccountingPoliciesUseOfEstimatesPolicies Note 3 - Significant Accounting Policies: Use of Estimates (Policies) false false R13.htm 000120 - Disclosure - Note 3 - Significant Accounting Policies: Basic (loss) Per Common Share (Policies) Sheet http://prtt/20140630/role/idr_DisclosureNote3SignificantAccountingPoliciesBasicLossPerCommonSharePolicies Note 3 - Significant Accounting Policies: Basic (loss) Per Common Share (Policies) false false R14.htm 000130 - Disclosure - Note 3 - Significant Accounting Policies: Recent Accounting Pronouncements (Policies) Sheet http://prtt/20140630/role/idr_DisclosureNote3SignificantAccountingPoliciesRecentAccountingPronouncementsPolicies Note 3 - Significant Accounting Policies: Recent Accounting Pronouncements (Policies) false false R15.htm 000140 - Disclosure - Note 4 - Related-party Transactions: Contributed Capital (Policies) Sheet http://prtt/20140630/role/idr_DisclosureNote4RelatedPartyTransactionsContributedCapitalPolicies Note 4 - Related-party Transactions: Contributed Capital (Policies) false false All Reports Book All Reports Process Flow-Through: 000010 - Statement - Condensed Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2013' Process Flow-Through: 000020 - Statement - Condensed Statements of Operations Process Flow-Through: 000030 - Statement - Condensed Statements of Cash Flows prtt-20140630.xml prtt-20140630.xsd prtt-20140630_cal.xml prtt-20140630_def.xml prtt-20140630_lab.xml prtt-20140630_pre.xml true true

Condensed Balance Sheets (USD $)	323 Months Ended
Condensed Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
ASSETS
Cash	$ 591	$ 681
Total Current Assets	591	681
TOTAL ASSETS	591	681
Accounts payable and accrued expenses	61,954	60,104
Accounts payable - related parties	165,476	23,939
Notes payable - related parties	34,439	24,940
Other accrued expenses	486,826
Total Current Liabilities	604,933	595,809
TOTAL LIABILITIES	604,933	595,809
Common stock; 100,000,000 shares authorized,at $0.005 par value, 44,573,012 and 44,573,012 shares issued and outstanding, respectively	222,865	222,865
Additional paid-in capital	8,357,980	8,354,980
Deficit accumulated during the development stage	(9,185,187)	(9,172,973)
Total Stockholders' Deficit	(604,342)	(595,128)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 591	$ 681

Condensed Statements of Operations (USD $)	3 Months Ended		6 Months Ended		323 Months Ended
Condensed Statements of Operations (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
REVENUES
Research and development					$ 1,353,540
Professional Fees	8,630	9,727	9,125	11,313	1,507,868
Executive compensation	1,500	1,500	3,000	3,000	5,897,730
General and administrative	45	46	89	90	447,209
Total Expenses	10,175	11,273	12,214	14,403	9,206,347
LOSS FROM OPERATIONS	(10,175)	(11,273)	(12,214)	(14,403)	(9,206,347)
Gain on sale of patents					(640,000)
Total Other Income					640,000
LOSS BEFORE DISCONTINUED OPERATIONS	(10,175)	(11,273)	(12,214)	(14,403)	(8,566,347)
LOSS FROM DISCONTINUED OPERATIONS					(4,340,551)
PROFIT LOSS	$ (10,175)	$ (11,273)	$ (12,214)	$ (14,403)	$ (12,906,898)
BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	$ 0.00	$ 0.00	$ 0.00	$ 0.00
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING	44,573,012	44,573,012	44,573,012	44,573,012

Document and Entity Information (USD $)	6 Months Ended
Document and Entity Information (USD $)	Jun. 30, 2014
Document and Entity Information:
EntityRegistrantName	PROTECT PHARMACEUTICAL Corp
DocumentType	10-Q
DocumentPeriodEndDate	Jun. 30, 2014
AmendmentFlag	false
EntityCentralIndexKey	0001493526
CurrentFiscalYearEndDate	--12-31
EntityCommonStockSharesOutstanding	44,573,012
EntityPublicFloat	$ 44,573,012
EntityFilerCategory	Smaller Reporting Company
EntityCurrentReportingStatus	No
EntityVoluntaryFilers	No
EntityWellKnownSeasonedIssuer	No
DocumentFiscalYearFocus	2014
DocumentFiscalPeriodFocus	Q2

Condensed Statements of Cash Flows (USD $)	6 Months Ended		323 Months Ended
Condensed Statements of Cash Flows (USD $)	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
OPERATING ACTIVITIES
Net loss	$ (12,214)	$ (14,403)	$ (12,906,898)
Common stock issued for services			9,904,653
Services contributed by officers	3,000	3,000	15,000
Common stock issued for research and development costs			1,250,000
Loss from disposition of subsidiary			564,300
Expenses paid on behalf of the Company	9,499	4,860	99,958
Gain on sale of patents			(640,000)
Accounts payable	1,850	(1,521)	61,955
Accounts payable - related parties	165,476	7,975	165,476
Prepaid expenses	491,667		491,667
Other accrued expenses			486,826
Net Cash Provided by Operating Activities	(90)	(89)	(507,062)
Proceeds from sale of patent			640,000
Net Cash Used in Investing Activities			640,000
Capital contributed by officer			13,046
Proceeds from related party payable			100
Repayment of related party payable			(145,493)
Net Cash Provided by (Used in) Financing Activities			(132,347)
NET INCREASE (DECREASE) IN CASH	(90)	(89)	591
CASH AT BEGINNING OF PERIOD	681	860
CASH AT END OF PERIOD	591	771	591
Common stock issued for prepaid services			$ 750,000